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Introduction and aim of the study
 
1. Oral Cancer
Epidemiology
Oral cancer, mainly consisting of oral squamous cell carcinoma (OSCC),  is the sixth most 
common cancer in the world1. The annual estimated incidence is approximately 275,000 
per year1. In Europe, oral cancer occupies the seventh position in the list of all cancers that 
may affect the body2. The highest incidence rates are observed in France and Hungary2.
In the Netherlands, oral cancer is the seventh most common cancer in males and the ninth 
most common cancer in females (www.cijfersoverkanker.nl). In most countries of the 
world, oral cancer is more common in men than in women1.     
Etiology
The etiology of OSCC is multifactorial. The risk factors can be divided in genetic,  
environmental and lifestyle habits3. The most important risk factors for OSCC are lifestyle 
habits, in particular tobacco use and excessive use of  alcoholic4-6. In Asia, also betel quid 
chewing is an important risk factor6,7. In a small subset of OSCC patients human  
papillomavirus (HPV) type 16 seems to play a role in the etiology8. 
Location 
The distribution of oral cancer in the mouth varies in different parts of the world. In Europe 
and the USA, the tongue is the most common site, amounting up to 40-50% of all oral  
cancers1. Buccal cancer is more common among Asian populations due to betel  
quid/tobacco chewing habits1.  
In almost 50% of the patients with an OSCC, it may be preceded by or associated with oral 
leukoplakia9.   
Treatment
Treatment of oral cancer may consist of surgery, radiotherapy, chemotherapy or  
combinations of these treatment modalities.  
The 5-year-survival rate of oral cancer for all tumour stages together is approximately 
50%-55%.  
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2. Oral premalignant disorders 
 
An oral premalignant disorder is defined as a morphologically altered tissue in which  
cancer is more likely to occur than in its apparently normal counterpart10. Oral  
premalignant disorders may appear as white or red lesions, referred to as leukoplakia and 
erythroplakia, respectively. The most common expression is leukoplakia. Other examples 
of premalignant disorders are submucous fibrosis and actinic cheilitis. There is an ongoing 
debate in the literature as whether oral lichen planus is a premalignant disorder. There is a 
tendency to, indeed, regard oral lichen as a premalignant disorder11. The annual malignant 
transformation rate of oral lichen planus being 0.5% or even less12. Also oral discoid lupus 
erythematosus is often mentioned to be a premalignant disorder. The present text will focus 
on leukoplakia with just a few remarks on erythroplakia. 
 
2.1. Oral leukoplakia
Definition 
Oral leukoplakia is defined by the WHO as ‘a white plaque of questionable risk having  
excluded (other) known diseases or disorders that carry no increased risk for cancer’10. A 
list of definable white diseases and disorders, that may occur in the mouth and that do not 
carry an increased risk for the development of cancer, is presented in Table 113.  
The term leukoplakia can be used at different levels of certainty (C-factor) as a clinical 
term only (C1 or C2) or as a clinicopathological term (C3 or C4)14.
 
Epidemiology and etiology 
The estimated prevalence of oral leukoplakia worldwide is approximately 2%15.  There 
is no strong preference for gender. Oral leukoplakia usually occurs after the age of 30-40 
years. The use of tobacco is an important etiologic factor16-19. Oral leukoplakia is six times 
more common in smokers than in non-smokers20. Also alcohol is a risk factor21. The  
possible etiologic role of the human papilloma virus (HPV) in oral leukoplakia is as yet 
unclear22,23. 
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   Table 1 White diseases and disorders that carry no increased risk for the development of  
     oral cancer 
 
Lesion Main diagnostic criteria
Alveolar ridge keratosis* Clinical aspect
Aspirin burn History of local application of asprin tablets
Candidasis, pseudomembranous** Clinical aspect (pseudomembranes, often  
symmetrical pattern)
Frictional lesion Disappearance of the lesion within four weeks after 
elimination of the suspected mechanical irritation 
(e.g. habit of vigorous toothbrushing); it is a  
retrospective diagnosis only
Hairy leukoplakia Clinical aspect (bilateral localization on the borders 
of the tongue); histopathology (incl. EBV)
Lesion caused by a dental  
restoration (often amalgam)
Disappearance of the anatomically closely related 
(amalgam) restoration within four weeks after its 
replacement; therefore, it is a retrospective diagnosis 
only
Leukoedema Clinical aspect (incl. symmetrical pattern)
Lichen planus*** Clinical aspect (incl. symmetrical pattern);  
histopathology is not diagnostic by its own
Linea alba Clinical aspect (incl. location on the line of  
occlusion in the cheek mucosa)
Lupus erythematosus**** Clinical aspect (incl. symmetrical pattern); almost 
always cutaneous involvement as well
Morsicatio (habitual chewing or 
biting of the cheek, tongue, lips)
History of habitual chewing or biting; clinical  
aspects
Papilloma and allied lesions, e.g. 
multifocal epithelial hyperplasia
Clinical aspect; histopathology
Syphilis, secondary (‘mucous 
patches’)
Clinical aspect; demonstration of T. pallidum;  
serology
Smokers’ lesion Disappearance of the lesion within four weeks after 
cessation of the tobacco habits; it is a 
retrospective diagnosis only
Smokers’ palate (‘stomatitis  
nicotinica’)
Clinical aspect; history of smoking
White sponge nevus Family history; clinical aspect (often symmetrical 
pattern)
*The term alveolar ridge keratosis is a poor term, since in most cases this term seems to be used as a clinical 
term only, not being based on histopathologic findings of keratosis 
** There is no consensus in the literature whether or not to recognize a hyperplastic subtype of oral  
candidasis: some prefer to refer to these lesions as Candida-associated leukoplakia. 
*** There is an ongoing discussion in the literature about the possible premaligant nature of oral lichen planus. 
**** There is limited evidence in the literature about the premalignant nature of oral discoid lupus  
erythematosus.
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Clinical aspects
Clinically, a distinction can be made between homogenous (flat, thin or wrinkled, uniform 
white in colour) and non homogeneous (white or white-and-red- sometimes referred to as 
erythroleukoplakia- , either speckled, nodular or verrucous) leukoplakia  
(Figure 1, 2 and 3) 10. Proliferative verrucous leukoplakia is a subtype of  non  
homogeneous, verrucous leukoplakia24,25.  
Oral leukoplakia may occur at any site in the oral cavity, e.g. tongue, floor of mouth 
(FOM), lower lip, hard palate, buccal mucosa, upper alveolus and gingiva, lower alveolus 
and gingiva, and also at multiple sites. 
Homogeneous leukoplakia is usually asymptomatic, while non homogeneous leukoplakia, 
in particular erythroleukoplakia, is often associated with a painful or itching sensation. 
 
Histopathological aspects
Histopathologically, oral leukoplakia can be divided in dysplastic and non dysplastic  
leukoplakias. The criteria used for diagnosing epithelial dysplasia are a combination of  
architectural changes and cytological atypia26. The WHO 2005 classification recognizes 
five histopathological stages in epithelial precursor lesions, e.g. squamous hyperplasia with 
or without hyperkeratosis, mild dysplasia, moderate dysplasia, severe dysplasia and  
carcinoma in situ26. The criteria used for diagnosing dysplasia are listed in Table 226. A 
limitation of dysplasia grading is its relative subjective character, indicated by a high  
inter- and intra-examiner variability in the assessment of dysplasia26-30. 
 
   Table 2 Criteria used for diagnosing dysplasia 
 
Architecture Cytology
Irregular epithelial stratification Abnormal variation in nuclear size (anisonucleosis)
Loss of polarity of basal cells Abnormal variation in nuclear shape (nuclear  
pleomorphism)
Basel cell hyperplasia Abnormal variation in cell size (anisocytosis)
Drop-shaped rete ridges Abnormal variation in cell shape (cellular  
pleomorphism)
Increased number of mitotic  
figures
Increased nuclear–cytoplasmic ratio
Abnormally superficial mitoses Increased nuclear size
Pre-mature keratinization in single 
cells (dyskeratosis)
Atypical mitotic figures
Keratin pearls within rete ridges Increased number and size of nucleoli
Hyperchromasia
Chapter 1
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Figure 1 Homogeneous oral leukoplakia           Figure 2 Non homogeneous oral (eryhto)
leukoplakia
Figure 3 Non homogeneous, verrucous 
leukoplakia    
Figure 5 Oral erythroplakia
Figure 4a Oral leukoplakia Figure 4b Malignant transformation of the 
oral leukoplakia four years later       
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Malignant transformation
The annual malignant transformation rate of oral leukoplakia differs in different parts of 
the world. In Western Europe, the  annual malignant transformation rate is approximately 
1%-2% (Figure 4a and 4b) 31. Several factors have been suggested to predict an increased 
risk of malignant transformation of oral leukoplakia, such as high age, female gender,  
absence of tobacco habits, non homogeneous clinical appearance, large size of the lesion, 
oral subsite such as floor of the mouth and tongue, high degree of epithelial dysplasia, loss 
of heterozygosity, immunohistochemical expression of surviving and matrix  
metalloproteinase 9, and DNA content31-38. Malignant transformation may occur at the site 
of the oral leukoplakia, but may also occur at a different site in the mouth or in the head 
and neck region. 
 
Management and follow-up 
In case of a definitive clinical diagnosis (Certainty factor 2) of oral leukoplakia, it is  
recommend to take a biopsy to exclude a possible definable lesion (Table 1)13,14,31, to assess 
the presence and, if present, degree of dysplasia and to rule out the possible presence of an 
oral squamous cell carcinoma. Further management of oral leukoplakia may consist of  
surgical excision, laser surgery, CO2 laser vaporisation or observation only39,40.  
Unfortunately, removal of leukoplakia does not really seem to prevent the development 
of a squamous cell carcinoma, either at the site of the leukoplakia or elsewhere in the oral 
cavity or the upper aerodigestive tract. 
There are no strict guidelines for the duration and frequency of follow-up examinations 
and the efficacy of such follow-up program. In general, lifelong follow-up examination is 
advised at 3-6 months intervals both in patients who have been treated for their leukoplakia 
as in those who have not31. 
 
2.2. Oral erythroplakia
Oral erythroplakia is defined by the WHO as ‘a fiery red patch that cannot be characterized 
clinically or pathologically as any other definable disease’ (Figure 5) 10,41. Oral  
erythroplakia is much less common than oral leukoplakia, but the potential for malignant 
transformation is much higher. This subject will not be discussed here any further.
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3. Aim of the present study
The aim of the present study was to evaluate the definition of oral leukoplakia, as being 
proposed by the WHO in 2005 and to evaluate the present molecular, clinical and  
histopathological factors of oral leukoplakia, including the follow-up of a cohort of patients 
after treatment or observation only.  
In chapter 2, an evaluation will be presented of the definition of oral leukoplakia, proposed 
by the WHO in 2005, taking into account a classification and staging system, including the 
use of a diagnostic Certainty factor.  
In chapter 3, an evaluation will be reported of the definition of proliferative verrucous  
leukoplakia (PVL). PVL was first described by Hansen et al.24. Cerero Lapiedra et al 
(2010) proposed diagnostic criteria of PVL using a set of major and minor criteria25. Some 
of these criteria are well accepted, but others are somewhat debatable. Therefore, a  
modified set of criteria has been proposed. 
In chapter 4, the treatment results of CO2-laser vaporisation in a well defined cohort of 
patients with oral leukoplakia are presented. 
In chapter 5, the factors that possibly predict malignant transformation in a well defined 
cohort of patients with a long-term follow-up will be reported.  All leukoplakias were 
staged according to a clinicopathological classification and staging system. Furthermore, 
a diagnostic Certainty factor has been used with which the diagnosis has been established.  
In chapter 6, the possible difference between DNA ploidy measurements using either flow 
cytometry (FCM-DNA) or image cytometry (ICM-DNA) in a well defined cohort of  
patients with oral leukoplakia has been described. This study is a continuation of the study 
of Bremmer et al.32. Relations between DNA ploidy and the histopathological grading and 
other clinical parameters, such as gender, smoking habit, alcohol consumption,  
homogeneity, size and location of the lesion have been investigated. 
In chapter 7, a summary, conclusions  and recommendations are presented.  
In  hoofdstuk 8, the summary, conclusions and  recommendations are presented in Dutch. 
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Abstract
The aim of the present study was to evaluate the definition of oral leukoplakia, proposed 
by the WHO in 2005 and taking into account a previously reported classification and  
staging system, including the use of a Certainty factor of four levels with which the  
diagnosis of leukoplakia can be established. 
           In the period 1997-2012 a hospital-based population of 275 consecutive patients 
with a provisional diagnosis of oral leukoplakia has been examined. In only 176 patients 
of these 275 patients a firm diagnosis of leukoplakia has been established based on strict 
clinicopathological criteria. The 176 patients have subsequently been staged using a  
classification and staging system based on size and histopathologic features. 
           For use in epidemiological studies it seems acceptable to accept a diagnosis of  
eukoplakia based on a single oral examination (Certainty level 1). For studies on  
management and malignant transformation rate the recommendation is made to include  
the requirement of histopathologic examination of an incisional or excisional biopsy, 
 representing Certainty level 3 and 4, respectively. This recommendation results in the  
following definition of oral leukoplakia: “A predominantly white lesion or plaque of  
questionable behaviour having excluded, clinically and histopathologically, any other  
definable white disease or disorder”. Furthermore, we recommend the use of strict  
diagnostic criteria for predominantly white lesions for which a causative factor has been 
identified, e.g. smokers’ lesion, frictional lesion and dental restoration associated lesion.  
Keywords: oral epithelial dysplasia, oral leukoplakia, potentially malignant oral disorders
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Introduction
The estimated prevalence of oral leukoplakia worldwide is approximately 2% 1, with an  
annual malignant transformation rate into oral squamous cell carcinoma (OSCC) of  
approximately 1% 2. In 1978, oral leukoplakia was defined by the World Health  
Organization (WHO) as: “a white patch or plaque that cannot be characterized clinically or 
pathologically as any other disease” 3. At an international conference in 1984, an addition 
was made to the 1978 WHO definition: “oral leukoplakia is not associated with any  
physical or chemical causative agent except the use of tobacco” 4. Thereafter, in 1986, the 
definition of oral leukoplakia has been changed into: “a predominantly white lesion of the 
oral mucosa that cannot be characterized as any other definable disease” 5. In 1997, the 
phrase: “any other definable disease” was replaced by “any other definable lesion” 6. 
 In 2002, it was recommended to make a distinction between a provisional clinical  
diagnosis of oral leukoplakia and a definitive one7. A provisional diagnosis was made when 
a lesion at the initial clinical examination could not be clearly diagnosed as either  
leukoplakia or a definable lesion. In case of a provisional clinical diagnosis, Certainty  
factor 1 was assigned. A definitive clinical diagnosis of leukoplakia was made after  
unsuccessful elimination of suspected aetiological factors or in the absence of such  
factors, assigning Certainty factor 2. Certainty factor 3 was assigned when  
histopathological examination of an incisional biopsy did not show the presence of a  
definable lesion. In case of an excisional biopsy or surgical excision, performed after an  
incisional biopsy, Certainty factor 4 was assigned based on histopathological examination 
of the surgical specimen.  
 In 2005, the definition was changed by the WHO into: “a white plaque of  
questionable risk having excluded (other) known diseases or disorders that carry no  
increased risk for cancer” 8. A list of definable white diseases and disorders, that may occur 
in the mouth, is presented in Table 1. In case of a predominantly red appearance, the term 
erythroplakia is applied. This entity will not be discussed here any further. 
 The aim of the present study was to evaluate the definition of oral leukoplakia,  
proposed by the WHO in 2005 and taking into account the previously mentioned  
classification and staging system (Table 2), including the use of a Certainty factor (Table 
3). The management results in these patients, including the issue of malignant  
transformation, will be reported separately. 
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Table 1 White diseases and disorders that carry no increased risk for the development of 
oral cancer
Lesion Main diagnostic criteria
Aspirin burn History of local application of asprin tablets
Candidasis, pseudomembranous* Clinical aspect (pseudomembranes, often sym-
metrical pattern)
Frictional lesion Disappearance of the lesion within four weeks after 
elimination of the suspected mechanical irritation
(e.g. habit of vigorous toothbrushing); it is a retro-
spective diagnosis only
Hairy leukoplakia Clinical aspect (bilateral localization on the borders 
of the tongue); histopathology (incl. EBV)
Lesion caused by a dental restoration 
(often amalgam)
Disappearance of the anatomically closely related 
(amalgam) restoration within four weeks after its
replacement; therefore, it is a retrospective diagno-
sis only
Leukoedema Clinical aspect (incl. symmetrical pattern)
Lichen planus** Clinical aspect (incl. symmetrical pattern); histopa-
thology is not diagnostic by its own
Linea alba Clinical aspect (incl. location on the line of occlu-
sion in the cheek mucosa)
Lupus erythematosus Clinical aspect (incl. symmetrical pattern); almost 
always cutaneous involvement as well
Morsicatio (habitual chewing or biting 
of the cheek, tongue, lips)
History of habitual chewing or biting; clinical as-
pects
Papilloma and allied lesions, e.g. mul-
tifocal epithelial hyperplasia
Clinical aspect; histopathology
Syphilis, secondary (‘mucous patch-
es’)
Clinical aspect; demonstration of T. pallidum; se-
rology
Smokers’ lesion Disappearance of the lesion within four weeks after 
cessation of the tobacco habits; it is a
retrospective diagnosis only
Smokers’ palate (‘stomatitis nicoti-
nica’)
Clinical aspect; history of smoking
Verruceus carcinoma Histopathology
White sponge nevus Family history; clinical aspect (often symmetrical 
pattern)
 
* There is no consensus in the literature whether or not to recognize a hyperplastic subtype 
of oral candidasis: some prefer to refer to these lesions as Candida-associated leukoplakia.
** There is an ongoing discussion in the literature about the possible premaligant nature of 
oral lichen planus.
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Table 2 Classification and staging system for oral leukoplakia (OL-system)
 L (size of the leukoplakia)
L
1 
Size of single or multiple leukoplakias together <2 cm
L
2 
Size of single or multiple leukoplakias together 2-4 cm
L
3 
Size of single or multiple leukoplakias together >4 cm
Lx Size not specified 
P (pathology)
P
0 
No epithelial dysplasia (includes “perhaps mild epithelial dysplasia”)
P
1 
Mild or moderate epithelial dysplasia
P
2 
Severe epithelial dysplasia (includes “perhaps carcinoma in situ”) 
Px Absence or presence of epithelial dysplasia not specified in the pathology   report
 OL-staging system
Stage 1 L
1
P
0
Stage 2 L
2
P
0
Stage 3 L
3
P
0
 or L
1
L
2
P
1
Stage 4 L
3
P
1
 or any L P2
General rules of the OL-staging system 
1. If there is doubt concerning the correct L category to which a particular case should be           
    allotted, than the lower (i.e. less advanced) category should be chosen. This will also be         
    reflected in the stage grouping. 
2. In case of multiple biopsies of single leukoplakia or biopsies taken from multiple  
    leukoplakias the highest pathological score of the various biopsies should be used. 
3. Distinct carcinoma in situ has been excluded from this classification. 
4. For reporting purposes the oral subsite according to the ICD-DA should be mentioned              
    (World Health Organisation, International Classification of Diseases. Tenth Revision.  
    Application to Dentistry and Stomatology, ICD-DA, Geneva, 1992).
Table 3 Certainty (C)-factor of a diagnosis of oral leukoplakia2 
 
C
1
 Evidence from a single visit, applying inspection and palpation as the only diagnosis 
means (Provisional clinical diagnosis), including a clinical picture of the lesion.
C
2
 Evidence obtained by a negative result of elimination of suspected etiologic factors, e.g. 
mechanical irritation, during a follow-up period of 6 weeks (Definitive clinical diagnosis)
C
3
 As C
2
, but complemented by pretreatment incisional biopsy in which, histopathologically, 
no definable lesion is observed (Histopathologically supported diagnosis) 
C
4
 Evidence following surgery and pathologically examination of the resected specimen
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Material and methods
Patients
For the purpose of this retrospective study, 295 consecutive patients were included with a 
provisional clinical diagnosis of oral leukoplakia and being documented with at least one 
clinical picture at admission. In this study, oral leukoplakia is defined according to the 
WHO 2005 definition. All patients were referred to the Department of Oral and  
Maxillofacial Surgery and Oral Pathology at VUmc/ ACTA, Amsterdam, The Netherlands 
between 1997 and 2012. Exclusion criteria were patients with a previous or concomitant 
OSCC (n = 20). The remaining group of 275 patients consisted of 112 men and 163  
women, with a mean age of 57 years (range 17-98 years). 
 In 171 patients a possible causative factor was identified, such as a dental  
restoration (“contact lesion”), mechanical irritation (“frictional lesion”) or tobacco use 
(“smokers’ lesion”), as being defined in Table 1. A maximum of four weeks was observed 
for evaluation of the result of cessation of the suspected causative factor. The use of  
tobacco and alcohol was registered in a simplified manner as being user, nonuser or  
unknown. 
 The location of the leukoplakia was specified according to eight subsites: 1) tongue, 
2) floor of mouth (FOM), 3) lower lip, 4) hard palate, 5) buccal mucosa, 6) upper alveolus 
and gingiva, 7) lower alveolus and gingiva and 8) multiples sites (Table 4). 
 Clinically, a distinction was made between homogeneous (flat, thin, uniform white 
in colour) and nonhomogeneous (white or white-and-red, - erythroleukoplakia - either 
speckled, granular, nodular or verrucous) (Table 4) 2. Proliferative verrucous leukoplakia 
(PVL) is a subtype of verrucous leukoplakia, being characterized by multifocal  
presentation, resistance to treatment and a high rate of malignant transformation9. This  
subtype will not be discussed here any further in detail. 
 In all cases of a definitive clinical diagnosis of leukoplakia, the taking of a biopsy 
was recommended not later than four weeks (Fig.1). The absence or presence of epithelial  
dysplasia has been recorded in three categories, being 1) no epithelial dysplasia or perhaps 
mild epithelial dysplasia (P
0
), 2) mild or moderate epithelial dysplasia (P
1
), and 3) severe 
epithelial dysplasia, possibly carcinoma in situ (P
2
). The size, presence and grade of  
epithelial dysplasia, if present, were grouped by means of the OL-classification and staging 
system (Table 2). 
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 The design of this study adheres to the code for proper secondary use of human  
tissue of the Dutch Federation of Biomedical Scientific Societies (http://www.federa.org). 
 
Table 4 Demographic, aetiologic and clinical data of 275 patients with a provisional  
clinical diagnosis of oral leukoplakia (Certainty factor 1) 
Variable Number
Gender Male 112
Female 163
Age (years) Average 57
Minimum 17
Maximum 98
Tobacco habits Use 141
Non use 117
Unknowm 17
Alcohol consumption Use 123
Non use 43
Unknown 109
Homogeneity Homogeneous 145
Non homogeneous 130
Location Tongue 71
Floor of mouth 45
Lower lip 13
Hard palate 18
Buccal mucosa 26
Upper alv. and gingiva 26
Lower alv. and gingiva 29
Multiple sites 47
 
Results
In this study, 275 patients with a provisional clinical diagnosis of oral leukoplakia were  
included (Certainty factor 1). There were 171 white lesions with possible causes, such 
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as mechanical irritation, direct contact with a dental restoration or tobacco habits. In 10 
patients a distinct regression or even complete disappearance of the lesion was observed. 
Thirteen patients did not show up for the assessment of the elimination of these possible 
causes. In the remaining 148 patients no response was observed, resulting in a definitive 
clinical diagnosis (Certainty factor 2). In 104 patients there were no possible causes, also 
resulting in a definitive clinical diagnosis (Certainty factor 2); four of these patients did not 
show up for the taking of a biopsy. As a result 248 patients were diagnosed with a  
Certainty factor 2. 
 Of the 248 patients with a definitive clinical diagnosis of oral leukoplakia, a biopsy 
was taken in only 181 patients. In five patients the histopathological examination resulted 
in a “definable lesion” (Table 1), including two cases of (verrucous) squamous cell  
carcinoma. In the remaining 176 patients, 109 incisional biopsies (Certainty factor 3) and 
67 excisional biopsies (Certainty factor 4) were performed.  
 Of the 109 patients in whom an incisional biopsy was taken, 34 showed various 
degrees of epithelial dysplasia, while in 75 patients no dysplasia was observed. In these 
patients treatment consisted of additional surgical excision (n = 18), CO
2
 laser vaporisation 
(n = 33) and observation (n = 58). In case of additional surgical excision a specimen was 
available for additional histopathological examination. In five of the 18 patients the final 
histopathological examination resulted in a different P-classification; four patients were 
upgraded from stage 1 to stage 3, while one patient was downgraded from stage 3 to stage 
1.  
 In 67 patients in whom an excisional biopsy was taken, various degrees of  
epithelial dysplasia have been observed in 28 patients. In the remaining 39 patients no  
dysplasia was observed. 
 In the 67 patients in whom no possible cause could be identified, no biopsy was 
taken within a period of four weeks after the first admission. In some of these patients a 
biopsy was taken at a later stage, while others were lost to follow-up. 
 The results of the diagnostic process are shown in Figure 1, while the results of the 
OL-staging are shown in table 5.
 
Discussion
In the present study, 275 patients with a provisional clinical diagnosis of oral leukoplakia 
were included (Certainty factor 1). Based on strict definitions only 176 of the initially 275 
patients have been diagnosed with a definitive clinicopathological diagnosis of oral  
leukoplakia (Certainty factor 3 or 4). Therefore, the use of strict criteria for the diagnosis  
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Table 5 Size, histopathology and stage in 176 patients with a definitive clinicopathological 
diagnosis of oral leukoplakia (Certainty factor 3 or 4) 
Size L
1
87
L
2
48
L
3
41
Dysplasia P
0
114
P
1
45
P
2
17
OL-staging system Stage 1 55
Stage 2 35
Stage 3 58
Stage 4 28
 
of leukoplakia is recommended in reporting treatment results and also in reporting the  
results of epidemiological studies.  
 The taking of a biopsy should be considered before the attempt of elimination of a 
possible cause, particularly in case of symptoms. In the past, we have encountered, indeed, 
an occasional patient with a clinical diagnosis of leukoplakia in whom a squamous cell  
carcinoma was already present in the biopsy taken at the first admission. 
 It is known that leukoplakia in patients with tobacco habits might be reversible if 
patients give up their smoking habits11,12. Therefore, these patients should be advised to 
give up their habits. If successful and if the white lesion regresses within a somewhat  
arbitrarily chosen period of no more than four weeks the provisional clinical diagnosis of 
such lesion should, in retrospect, be changed into “smokers’ lesion”. It is well appreciated, 
that it actually may take more than four weeks for such a smokers’ lesion to completely 
disappear. Others have shown resolvement of these lesions after cessation of the tobacco 
habits for six weeks13. A longer period of observation may be allowed provided a prior  
biopsy has not shown the presence of any degree of epithelial dysplasia. When the patient 
is not able or willing to give up the tobacco habits and in persistence of the lesion, the  
relevance of applying the term “tobacco-associated leukoplakia” seems questionable. 
 Another possible reversible white lesion is the frictional lesion caused by  
mechanical irritation. This lesion is sometimes referred to as “frictional keratosis” 14-16. The 
term “lesion” is preferred because “keratosis” is actually a histopathological term.  
Similarly as in smokers’ lesion we recommend to restrict a final diagnosis of frictional  
 CHAPTER
         2
The relevance of uniform reporting in oral leukoplakia: Definition, 
certainty factor and staging based on experience with 275 patients 
33
lesion to cases where the lesion has disappeared after elimination of the mechanical cause, 
within a somewhat arbitrarily chosen period of no more than four weeks. As in a  
smokers’ lesion, the definitive diagnosis of frictional lesion can only be made in retrospect. 
The same applies to “contact lesion” caused by amalgam. 
 Furthermore, there is room for discussion about the diagnosis candidiasis versus 
Candida-associated leukoplakia, particularly if located at the commissures of the lips and 
the dorsal surface of the tongue. If such lesions regress or disappear after antifungal  
treatment within the previously mentioned period of four weeks there is no justification to 
call such lesions leukoplakias any longer. However, in case of persistence, the diagnosis of 
(Candida-associated) leukoplakia remains valid. 
 Although alcohol might play a role in the aetiology of oral leukoplakia, no studies 
are available in which the results of cessation of alcohol habits as a single factor has been 
examined. Perhaps there is such an entity of a leukoplakialike lesion caused by alcohol 
(“alcohol lesion”) that disappears after quitting the habit. 
 In five out of 181 patients with a definitive clinical diagnosis of leukoplakia the 
final diagnosis has been changed into papilloma, cheilitis actinica, verrucous carcinoma, 
squamous cell carcinoma, and lichen planus. As reported elsewhere17, we hesitate to accept 
a histopathological diagnosis of lichen planus as a final diagnosis. Rather, we prefer the 
description “compatible with lichen planus”. The issue of “lichenoid dysplasia” has been 
thoroughly discussed in the literature18. We discourage the use of such term since it,  
erroneously, may suggest dysplastic changes in oral lichen planus. 
 It is well recognized that the assessment of the presence and degree of epithelial 
dysplasia carries some subjectivity, reflected in a distinct intra- and inter-observer  
variation19,20. In the present study, the absence or presence of epithelial dysplasia has been 
recorded into three categories, being 1) no or perhaps mild epithelial dysplasia (P
0
), 2) mild 
or moderate epithelial dysplasia (P
1
), and 3) severe epithelial dysplasia, possibly carcinoma 
in situ (P
2
) (Table 2). We prefer a three category system above a four category system to 
reduce the intra- and inter-observer variation between oral pathologists. Therefore,  
‘perhaps mild epithelial dysplasia’ was included in the first grade.  In the WHO monograph 
on Head and Neck Tumours severe epithelial dysplasia is recognized as a separate entity 
from carcinoma in situ21. In the present study we have followed these recommendations. 
In case of carcinoma in situ the diagnosis of leukoplakia is abandonned (Table 2). Kujan et 
al.22 applies only two histopathological grades, being 1) “low risk” (less than four  
architectural changes or less than four cytological changes), and 2) “high risk” (at least 
four architectural changes and five cytological changes). In this system, the authors used 
the architectural and cytological changes that have been described in the previously  
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mentioned WHO monograph (Table 6) 21. At present, there is insufficient justification to 
include one or more biological markers that may have predictive value in malignant  
transformation, such as DNA ploidy, in a staging system. 
 In the 1978 WHO definition of oral leukoplakia it has been explicitly stated that the 
term leukoplakia is unrelated to the absence or presence of epithelial dysplasia. Therefore, 
we discourage the use of the term leukoplakia as a histopathological term. In case of a  
biopsy of a leukoplakia, the pathologist is advised to always report the absence or presence 
of epithelial dysplasia and its degree. 
 There are actually no strict criteria how to make a distinction clinically between 
verrucous leukoplakia and verrucous carcinoma. Histopathologically, several papers have 
been published about the histopathological difference between verrucous hyperplasia and 
verrucous carcinoma, still leaving room for discussion23.  
 There is also room for discussion about the presently proposed classification of the 
size of a leukoplakia in three groups (< 2 cm, 2-4 cm, > 4 cm). In fact, the classification is 
more or less based on the T classification of oral squamous cell carcinoma. In a study by 
Holmstrup et al. a surface of 200 mm2 was shown to be of relevance with regard to the risk 
of malignant transformation24. Therefore, one might consider the use of a size classification 
in two groups, being < 200 mm2 or > 200 mm2. 
Table 6 Criteria used for diagnosing dysplasia.19 
Architecture Cytology
Irregular epithelial stratification Abnormal variation in nuclear size (anisonucleosis)
Loss of polarity of basal cells Abnormal variation in nuclear shape (nuclear pleo-
morphism)
Basel cell hyperplasia Abnormal variation in cell size (anisocytosis)
Drop-shaped rete ridges Abnormal variation in cell shape (cellular pleomor-
phism)
Increased number of mitotic figures Increased nuclear–cytoplasmic ratio
Abnormally superficial mitoses Increased nuclear size
Pre-mature keratinization in single 
cells (dyskeratosis)
Atypical mitotic figures
Keratin pearls within
rete ridges
Increased number and size of nucleoli
Hyperchromasia
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 In the sixties of the past century a minimum size of 5 mm was required before  
being allowed to use the term leukoplakia25. Although there may be some practical value in 
re-introducing a minimum size in the definition of leukoplakia, we hesitate to do so.  
Another part of previous definitions of leukoplakia has been the requirement of a non 
removable nature of the white lesion, apparently meant to separate pseudomembranous 
candidiasis from leukoplakia. The adjective “non removable” seems, indeed, to have some 
practical value, but we do not recommend its re-use at present. 
 One may consider to include the oral subsite in the staging system. For instance, 
in some studies leukoplakias of the floor of the mouth and the tongue have been reported 
to more often transform into malignancy than leukoplakias at other subsites. However, 
in other parts of the world, e.g. India, leukoplakias at the buccal mucosa are more at risk. 
Therefore, we do not recommend to include the subsite in the staging system. 
 The clinical distinction between homogeneous and nonhomogeneous leukoplakia 
has shown to be a valuable predictor of possible malignant transformation24. In daily  
practice it is difficult to always correctly make the distinction between these two types in a 
reproducible manner. The same applies to the various subtypes of nonhomogeneous  
leukoplakias, such as speckled, nodular, granular and also the already mentioned  
(proliferative) verrucous types. Nevertheless, we suggest to maintain these descriptions. 
 The adjectives “premalignant”, “precancerous” and “potentially malignant”  
designate the increased risk of malignant transformation. At present, there seem no strong 
reasons to change the WHO preference for the use of “potentially malignant”. 
 It is well appreciated that a number of aspects of the presently discussed definition 
and staging system may not be equally valid in all parts of the world. We have taken notice 
of a recently proposed classification from India for potentially malignant disorders of the 
oral cavity26. Obviously, this new classification is not limited to the presently discussed  
entity of leukoplakia, but also includes entities such as lichen planus, oral submucous  
fibrosis, nutritional deficiencies and some inherited cancer syndromes. 
 It is beyond the aim of the present study to further discuss the possible value of  
diagnostic adjuncts, e.g. toluidine blue. This also applies to discussion on the various  
treatment modalities and the malignant transformation rate. Suggestions for uniform  
reporting of treatment results have been discussed elsewhere2.
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Conclusions
 Based on the results of the present study the use of strict diagnostic criteria for oral 
leukoplakia and allied white lesions is recommended. Furthermore, the presented  
classification and staging system seems valuable for comparing management results of  
patients with oral leukoplakia and also for use in epidemiological studies. 
 The recommendation is made to modify the present WHO definition of oral  
leukoplakia by adding the requirement of histopathologic examination in order to obtain a 
definitive clinicopathological diagnosis. As a result, we suggest: “A predominantly white 
lesion or plaque of questionable behaviour having excluded, clinically and  
histopathologically, any other definable white disease or disorder”. Furthermore, we  
recommend the use of strict diagnostic criteria for predominantly white lesions or diseases 
for which a causative factor has been identified, e.g. smokers’ lesion, frictional lesion and 
dental restoration associated lesion.  
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Abstract
Since its introduction in the literature in 1985, the term proliferative verrucous leukoplakia 
(PVL) has been the subject of an ongoing discussion with regard to its definition. 
Widespread or multifocal occurrence of oral leukoplakia is not just synonymous to PVL. 
In the present treatise the proposal is made to require the involvement of more than two 
oral subsites, a total added size of the leukoplakic areas of at least 3 centimeters, and a 
well documented period of at least five years of disease evolution being characterized by 
spreading and the occurrence of one or more recurrences in a previously treated area.
Keywords: oral premalignant lesions, oral leukoplakia, verrucous leukoplakia
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Introduction
The term proliferative verrucous leukoplakia (PVL) has been defined by Hansen et al. 
(1985) as a disease of unknown origin, that clinically often begins as a single white lesion 
and along time tends to become multifocal, growing slowly and progressively. It should 
be acknowledged that some lesions may initially be pinkish or even red rather than white. 
Hansen et al’s description of PVL includes the predilection for elderly women, a strong 
tendency to recur after treatment and, in many cases, inevitably, the development of  
squamous cell carcinoma. Tobacco habits were quite common in Hansen et al’s series. All 
sites in the oral cavity can be affected, not showing any preference for specific oral  
subsites. 
 Since Hansen et al’s publication many cases diagnosed as PVL have been  
published, questioning the etiology, diagnostic criteria and appropriate treatment. In  
general, the diagnostic criteria that have been used in the various studies are diverse and 
many cases actually seem to represent widespread, multifocal leukoplakia. Cerero Lapiedra 
et al. (2010) proposed diagnostic criteria of PVL using a set of major and minor criteria 
(Table I). Some of these criteria are well accepted, but others seem to be somewhat  
debatable. In this treatise both the major and minor diagnostic criteria will be commented 
upon.
Critical appraisal of the diagnostic criteria
In order to make the diagnosis of PVL, Cerero-Lapiedra et al (2010) proposed that one of 
the two following combinations of criteria mentioned in Table I should be met: 
1. Three major criteria (being E among them) or 
2. Two major criteria (being E among them) + two minor criteria.
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Major criteria
Major criterion A:
Cerero-Lapiedra et al (2010) considered involvement of keratinized mucosae (gingiva 
and palate) as the most frequently involved sites in PVL, although five out of seven case 
series on which their proposal was based on showed involvement of the buccal mucosa as 
the first or second most commonly affected site. It should be emphazised, as mentioned 
by Hansen et al, that any site of the oral cavity may be involved. Therefore, we suggest to 
limit criterion A to: “Leukoplakia involving more than two oral subsites, either separate or 
in continuity”. The following oral subsites are recognized: dorsum of the tongue (unilateral 
or bilateral), border of the tongue, cheek mucosa, alveolar mucosa or gingiva upper jaw, 
alveolar mucosa or gingiva lower jaw, hard and soft palate, floor of the mouth, upper lip 
and lower lip. 
Major criterion B: 
The presence of one or more verrucous or wartlike areas is, indeed, a condition sine qua 
non in the diagnosis of PVL.  
Major criterion C: 
Although spreading and/or enlarging during development is not exclusive for PVL and 
may occur in any type of leukoplakia,  we suggest to maintain this criterion.  
Major criterion D: 
Although recurrence in a previously treated area of leukoplakia is not exclusive for a  
diagnosis of PVL, it seems appropriate to maintain this criterion.  
Major criterion E: 
Cerero-Lapiedra et al (2010) mentioned that PVL starts as a simple hyperkeratosis, which 
can progress, with or without stages of various degrees of epithelial dysplasia, to verrucous 
hyperplasia, verrucous carcinoma or squamous cell carcinoma. However, this observation 
is not limited to PVL and is, therefore, difficult to accept as a criterion for PVL. 
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Minor criteria
Minor criterion a: 
Many single or multifocal leukoplakias (non-PVL), adding all the affected areas may 
measure 3 centimeters or more in size. There seems to be, indeed, some value in requiring 
a minimum size for a diagnosis of PVL. 
Minor criterion b: 
Since almost 20% of the cases reviewed by Cerero-Lapiedra et al, including Hansen et al’s 
paper, were males, female gender should not be included as a (minor) criterion for the  
diagnosis of PVL.
Minor criterion c: 
The percentage of smokers in the case series selected by Cerero-Lapiedra et al (2010) 
varied between 23% and 70%. Therefore, it does not seem justified to include being a  
non-smoker as a( minor) criterion of PVL. 
Minor criterion d: 
A period of diseases evolution of at least five years, as suggested by Cerero-Lapiedra is 
more or less in accordance with Hansen et al’s experience. 
Chapter 3
46
Table 1  Proposal of major and minor diagnostic criteria for PVL recommended by  
Cerero-Lapiedra et al (2010). 
       Major criteria (MC) Minor criteria (mc)
A A leukoplakia lesion with more 
than two different oral sites, which 
is most frequently found in the 
gingiva, alveolar processes and 
palate.
a An oral leukoplakia lesion that 
occupies at least 3 cm when adding 
all the affected areas.
B The existence of a verrucous area. b That the patient be female.
C That the lesions have spread or 
engrossed during development of the 
disease.
c That the patient (male or female) be a 
non-smoker.
D That there has been a recurrence in a 
previously treated area.
d A disease evolution higher than 5 
years.
E Histopathologically, there can be 
from simple epithelial hyperkeratosis 
to verrucous hyperplasia, verrucous 
carcinoma or oral squamous cell 
carcinoma, whether in situ or 
infiltrating.
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Table 2 Modified diagnostic criteria for PVL; all four criteria should be met
1. Leukoplakia showing the presence of verrucous or wartlike areas, involving more 
than two oral subsites. The following oral subsites are recognized: dorsum of the tongue 
(unilateral or bilateral), border of the tongue, cheek mucosa, alveolar mucosa or gingiva 
upper jaw, alveolar mucosa or gingiva lower jaw. hard and soft palate, floor of the 
mouth, upper lip and lower lip 
2. When adding all involved sites the minimum size should be at least three centimeters 
3. A well documented period of disease evolution of at least five years, being 
characterized by spreading and enlarging and the occurrence of one or more recurrences 
in a previously treated area 
4. The availability of at least one biopsy in order to rule out the presence of a verrucous 
carcinoma or squamous cell carcinoma
 
Conclusion and recommendation
The importance of the diagnosis of PVL lies in the awareness of both the clinician and 
pathologist that apparently innocent looking oral verrucous lesions, irrespective of their 
colour and irrespective of the presence of dysplasia may in time progress into verrucous 
carcinoma or squamous cell carcinoma. In view of our comments on the major and minor 
diagnostic criteria proposed by Cerero-Lapiedra et al, we suggest to simplify the diagnostic 
criteria of PVL by omitting the distinction between major and minor criteria as is shown in 
Table 2. Figure 1a, b, c and d, shows an example of a patient with PVL. 
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Figure 1a Red lesion at the upper alveolus 
and gingiva
Figure 1d Original magnification x100Figure 1c Multiple new lesions have been 
arisen at the right trigonum retromolare, 
right buccal mucosa and the right tuber 
maxillare                                                     
Figure 1b After CO2 laser vaporisation the 
lesion disappeared
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Abstract 
 
Objectives: The aim of the present study was to evaluate the treatment results of CO
2
-laser 
vaporisation in a well defined cohort of patients with oral leukoplakia.  
Material and methods: The group consisted of 35 patients. Before treatment, a clinical 
photograph and an incisional biopsy were performed in all cases. Also posttreatment  
results were documented with clinical photographs. The assessment of the treatment  
results was performed by an independent clinician who had not performed the treatment. 
The mean follow-up period was 61.9 months (range 12 to 179 months).  
Results: In 14/35 patients, there was a recurrence between 1 and 43 months (mean 18.7 
months), the annual recurrence rate being approximately 8%. In 3 of these patients,  
malignant transformation occurred at a later stage. In two other patients a malignancy  
occurred without a prior recurrence. In altogether 5/35 patients malignant transformation 
occurred in a mean period of 54 months, the annual malignant transformation rate being 
approximately 3%. 
Conclusions: The results in the present study are worse than those reported in the  
literature, perhaps due to the use of different diagnostic criteria for oral leukoplakia,  
differences in the employed laser technique, and assessment of possible recurrences by  
an independent clinician.
Keywords: oral leukoplakia, potentially malignant oral disorders, carbon dioxide laser,  
recurrence, malignant transformation
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Introduction
Oral leukoplakia is the most common potentially malignant disorder of the oral cavity. The 
estimated prevalence of oral leukoplakia worldwide is approximately 2% 1, with an annual 
malignant transformation rate into oral squamous cell carcinoma (OSCC) of 1-2% 2. Early 
detection and treatment are important in an attempt to prevent malignant transformation. 
          Conventional treatment of oral leukoplakia consists of surgical excision, laser  
surgery and laser vaporisation. For laser treatment, many types of lasers have been  
described such as carbon dioxide (CO
2
), NdYAG, argon and KTP  lasers3-5. CO
2
 laser 
vaporisation treatment is associated with minimal damage to the adjacent tissue, limited 
scarring, little wound contraction and low postoperative complications6-9. The aim of the 
present study was to evaluate the treatment results of CO
2
-laser in a well defined cohort of 
patients with oral leukoplakia. 
Material and methods
Patients
For the purpose of this retrospective study, 35 patients treated with CO
2
 laser vaporisation 
were included from a total population of 176 patients who were referred to the Department 
of Oral and Maxillofacial Surgery and Oral Pathology at VUmc/ ACTA, Amsterdam, The 
Netherlands, between 1997 and 2012 and in whom a definitive clinicopathological  
diagnosis of oral leukoplakia was established. 
          In our Institute, there is a traditional preference for surgical excision of leukoplakias 
above CO
2
 laser because of the availability of a surgical specimen for histopathological 
examination even in cases where a prior incisional biopsy was taken, particular in the case 
of moderate or severe epithelial dysplasia. In the present series, treatment with CO
2
 laser 
vaporisation was preferred above surgical excision in case of lesions larger than 2-3 cm, 
particularly if not well-circumscribed, and, as a rule, in the absence of moderate or severe 
dysplasia. The latter exclusion criterion has occasionally not been respected because of the 
site or the size of the lesion or because of a strong preference from the patients’ side. 
          The group of 35 patients consisted of 10 men and 25 women, with a mean age of 
55.5 years (range 26-87 years). Only patients with a minimum follow-up of 12 months 
were included. The use of tobacco and alcohol was registered in a simplified manner as  
being user, non user or unknown (Table 1). 
           In this study, oral leukoplakia was defined according to a slightly modified  
Chapter 4
54
definition proposed by the WHO in 2005 10: ‘A predominantly white plaque of questionable 
behaviour having excluded, clinically and histopathologically, any other definable white 
disease or disorder that carries no increased risk for cancer’. Clinically, a distinction was 
made between homogenous (flat, thin, uniform white in colour) and non-homogeneous 
(white or white-and-red, - erythroleukoplakia - either speckled, granular, nodular or  
verrucous) leukoplakia.  
 
        Table 1 Demographic, etiologic and clinical data of 35 patients with a definitive  
     clinicopathological diagnosis of oral leukoplakia treated with CO
2
 laser vaporisation
Total Recurrence OSCC
n  = 35 n = 14 n = 5
Variable
Gender Male 10 5 1
Female 25 9 4
Age (years) Average 55 53.7 59.4
Minimum 26 26 26
Maximum 87 78 81
Tobacco hab-
its
Use 17 6 3
Non use 6 8 1
Unknown 2 0 1
Alcohol con-
sumption
Use 18 7 2
Non use 7 2 1
Unknown 10 5 2
Homogeneity Homogeneous 10 6 1
Non homogeneous 25 8 4
Location Tongue 9 3 2
FOM 3 0 0
Lower lip 1 1 0
Hard palate 1 0 1
Buccal mucosa 3 2 1
Upper alv. and ging 3 2 0
Lower alv. and ging 6 2 0
Multiple sites 9 4 1
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 The location of leukoplakia was specified according to eight sites: 1) tongue, 2) 
floor of mouth (FOM), 3) lower lip, 4) hard palate, 5) buccal mucosa, 6) upper alveolus 
and gingiva, 7) lower alveolus and gingiva and 8) multiple sites (Table 1). In all patients, 
clinical photographs were taken both of the primary lesion and the recurrence, if  
applicable. The size, presence and degree of epithelial dysplasia were classified by means 
of an oral leukoplakia (OL)-classification and staging system (Tables 2 and 3) 2,11.  
 The CO
2
 laser system was a ‘Laser Vision®, type 40’ (Laservision GmbH & Co., 
Fuerth, Germany). Settings of the system were a super pulse frequency and a continuous 
wave. Output powers of 4-8 W were used. A smoke evacuator was used, and also a special 
mask and glasses. Treatment was often performed under local anaesthesia. If feasible, a 
margin of 2-3 mm around the lesion was taken. For postoperative care, a 0.12% 
 
Table 2 Classification and staging system for oral leukoplakias (OL-system) 
 L (size of the leukoplakia)
L
1 
Size of single or multiple leukoplakias together <2 cm
L
2 
Size of single or multiple leukoplakias together 2-4 cm
L
3 
Size of single or multiple leukoplakias together >4 cm
Lx Size not specified 
P (pathology)
P
0 
No epithelial dysplasia (includes “perhaps mild epithelial dysplasia”)
P
1 
Mild or moderate epithelial dysplasia
P
2 
Severe epithelial dysplasia (includes “perhaps carcinoma in situ”) 
Px Absence or presence of epithelial dysplasia not specified in the pathology   report
 OL-staging system
Stage 1 L
1
P
0
Stage 2 L
2
P
0
Stage 3 L
3
P
0
 or L
1
L
2
P
1
Stage 4 L
3
P
1
 or any L P2
General rules of the OL-staging system 
1. If there is doubt concerning the correct L category to which a particular case should be           
    allotted, than the lower (i.e. less advanced) category should be chosen. This will also be      
    reflected in the stage grouping. 
2. In case of multiple biopsies of single leukoplakia or biopsies taken from multiple  
    leukoplakias the highest pathological score of the various biopsies should be used. 
3. Distinct carcinoma in situ has been excluded from this classification. 
4. For reporting purposes the oral subsite according to the ICD-DA should be mentioned              
    (World Health Organisation, International Classification of Diseases. Tenth Revision.  
    Application to Dentistry and Stomatology, ICD-DA, Geneva, 1992).
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chlorhexidine mouthwash and Non-steroidal anti-inflammatory drugs analgesics were  
prescribed. 
  After treatment, patients were seen for follow up after 4 weeks. Thereafter, the  
patients were subsequently followed at six-month intervals. A local recurrence was defined 
as a leukoplakia arising within the borders of the treated area, independent of the size and 
independent of the time interval. The follow-up period ranged from 12 to 179 months with 
a mean of 61.9 months. The follow-up period started at the first visit of the patient to the 
clinic. It ended in case of lost to follow-up, death and development of OSCC at the site of 
oral leukoplakia or elsewhere in the oral cavity. 
 The design of this study adheres to the code for proper secondary use of human  
tissue of the Dutch Federation of Biomedical Scientific Societies (http://www.federa.org).
 
Table 3 Size, histopathology and stage in 35 patients with a definitive clinicopathological 
diagnosis of oral leukoplakia treated with CO
2
 laser vaporisation
Total Recurrence OSCC
n  = 35 n = 14 n = 5
Variable
Size L
1
11 2 1
L
2
13 6 2
L
3
9 6 2
Dysplasia P
0
25 10 3
P
1
6 2 1
P
2
4 2 1
OL-staging system Stage 1 8 2 0
Stage 2 8 3 1
Stage 3 14 7 3
Stage 4 5 2 1
 
Statistical analysis
Minimum, maximum, and mean values of continuous variables were calculated.  
Statistically significant relations were tested with the t-test and chi-square test. The clinical 
and histopathological variables, age, gender, smoking habit, alcohol consumption,  
homogeneity, dysplasia, size of the lesion and location were registered. The results were 
considered statistically significant if the P value was less than 0.05. For malignant  
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transformation and recurrence, a survival curve was plotted according to the Kaplan-Meier 
method. For all statistical analyses, SPSS 17.0 for Windows (SPSS Inc, Chicago, IL, USA) 
was used. 
 
Results
In 14/35 (40%) patients, there was a recurrence after CO
2
 laser vaporisation (5 men and 9 
women) (Figure 1 and 2). In patients with a recurrence, age ranged from 26-78 years (mean 
53.7-years). Patient and clinical factors of these patients are shown in Table 1 and 3. 
Figure 1a. Patient with oral leukoplakia 
before treatment
Figure 1b. No recurrence after a follow-up 
of 2 months
Figure 2a. Patient with oral leukoplakia 
before treatment
Figure 2b. Recurrence after a follow-up of 
4 months
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Among these patients the initial biopsy showed no dysplasia (P
0
) in 10 patients, while in 
two patients mild/moderate dysplasia (P
1
) and in two cases severe dysplasia (P
2
) was  
observed (Table 3). All recurrences appeared between 1 and 43 months (mean 18.7 
months) after treatment, the annual recurrence rate being approximately 8% (Figure 3). 
There were no statistically significant differences between the various parameters in the 
recurrence versus the nonrecurrence group. The management of the recurrence consisted of 
observation (n = 8), surgical excision (n = 5) and, in one case, again CO
2
 laser  
vaporisation.  
          In 5/35 (14%) patients treated with CO
2
 laser vaporisation, the oral leukoplakia 
transformed into an OSCC; one man and four women. Three of these patients experienced 
a previous recurrence. Age ranged from 26-81 years (mean 59.4-years). Patient and  
clinical factors of these patients are shown in Table 1 and 3. Among these patients, the  
initial biopsy showed no dysplasia in three patients (P
0
), a mild/moderate dysplasia in one 
patient (P
1
) and in one patient severe dysplasia (P
2
) (Table 3). The malignant  
transformations appeared between 32 and 90 months (mean 54 months), the annual  
malignant transformation rate being approximately 3% (Figure 4). There were no  
statistically significant differences in the variables between patients with and without  
malignant transformation.  
 A few patients complained about pain after CO
2 
laser vaporisation treatment. Of the 
total patient group, only one postoperative complication was recorded, consisting of  
temporary mental nerve anaesthesia. 
Discussion
In the present study, 35 patients with a definitive histopathological diagnosis of oral  
leukoplakia and treated with CO
2
 laser vaporisation were included.  Leukoplakia was  
defined  based on a modified WHO definition. Moreover, a classification and staging 
system has been used (Table 2) 2,11. Before CO
2
 laser vaporisation treatment, a clinical 
photograph was taken and an incisional biopsy were performed in all cases to determine 
the presence and degree of dysplasia. Furthermore, a period of not more than four weeks 
before treatment was observed to eliminate any possible causative factor, such as smoking, 
dental restorations, friction and candida infection.  
          In the present series, treatment with CO
2
 laser vaporisation was preferred above  
surgical excision in case of lesions larger than 2-3 cm, particularly if not  
well-circumscribed, and, as a rule, in the absence of moderate or severe dysplasia. The  
latter exclusion criterion has occasionally not been respected because of the site or the size 
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Figure 4 Kaplan-Meier analysis of malignant transformation in oral leukoplakia (n = 5)
Figure 3 Kaplan-Meier analysis of recurrence in oral leukoplakia (n = 14)
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of the lesion or because of a strong preference from the patients side. In case of epithelial 
dysplasia in the incisional biopsy, surgical excision has the advantage of providing a  
specimen for  
hispathological examination of the margin. In case of epithelial dysplasia in the surgical 
margins, additional treatment may be indicated.  
 Besides dysplasia, molecular markers might be helpful in the near future in  
predicting the risk of malignant transformation of oral leukoplakia and, thereby,  may be 
relevant in the type of treatment that should be instituted. At present,  DNA ploidy  
measurement might be useful in this respect12,13.  
 Unfortunately, no comparisons can be made between the treatment results of CO
2
 
laser vaporisation and cold knife surgical excision, because of different indications for both 
treatment modalities. In the literature, no randomized control trial studies are available to 
compare both treatment modalities with regard to the local recurrence rate and the risk of 
malignant transformation.  
          In the present study, an annual recurrence rate of approximately 8% was observed. 
In the literature, recurrence rates vary between 9.9% and 39.5% 5,9,14-21. Unfortunately, in 
most studies no annual recurrence rate have been calculated. Besides, comparison of the 
treatment results of CO
2
 laser vaporisation with other studies using CO
2
 laser vaporisation 
is hindered by the use of different definitions of oral leukoplakia and allied white lesions.  
          The assessment of the treatment results was performed by an independent  
clinician who had not performed the treatment. In some patients it was difficult to  
determine whether the leukoplakia was a persistent lesion after CO
2 
laser vaporisation or 
a recurrence. Occasionally, some small white lesions (<5mm) were diagnosed within the 
borders of the treated area. All these lesions were registered as a recurrence. This could  
explain the high recurrence rate in the present study compared to the results of other  
studies. Furthermore, the results of CO
2
  laser vaporisation treatment may to some extent 
be influenced by employed laser technique.  
          No statistically significant differences were found in the present study between  
clinical and histopathological parameters of the primary oral leukoplakia, recurrences and 
cases of malignant transformation. It does not seem that this could be explained by the 
small number of patients in this study, since the p-values were not even close to the  
significance level. 
          In other laser treatment studies, smokers carried a significantly higher risk for  
recurrence than ex smokers and non smokers 15,22. Also widespread or multiple lesions 
were found to be independent prognostic factors for recurrence 15.   
          There were 5/35 patients of whom the oral leukoplakia progressed to an OSCC 
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(14%), the annual malignant transformation rate being approximately 3%. In the literature, 
malignant transformation rates in patients treated with CO
2
 laser vaporisation vary between 
1.1% and 11.4% 5,16-19,23. However, in most studies no annual malignant transformation 
rates have been calculated. Of the five patients with a progression to cancer in the present 
study, three patients had a previous recurrence after CO
2
 laser vaporisation treatment. In 
another recent study, multivariate analysis showed that recurrence (relative risk = 9.40) 
was an independent prognostic factor for malignant transformation 23. 
           With regard to recurrences, the results in the present study are worse than those  
reported in the literature, perhaps due to a different use of diagnostic criteria for oral  
leukoplakia and allied white lesions and perhaps also due to a different way of assessing 
recurrence. The malignant transformation rate in the present study is more or less  
comparable with that of other studies. 
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Abstract
OBJECTIVES: Oral leukoplakia is a potentially malignant disorder of the oral mucosa. 
The aim of the present retrospective study was to identify the factors that possibly predict 
malignant transformation in a well defined cohort of patients with a long-term follow-up. 
All leukoplakias were staged according to a clinicopathological classification and staging 
system. Furthermore, a Certainty factor has been used with which the diagnosis has been 
established.  
MATERIAL AND METHODS: The group consisted of 144 patients. The size, presence 
and degree of epithelial dysplasia were incorporated in a clinicopathological classification 
and staging system. Initial management consisted of surgical excision, CO
2 
laser  
vaporisation or observation only. The mean follow-up period was 51.2 months (SD= 39.33, 
range 12-179 months). 
RESULTS: In 16/144 patients (11%) malignant transformation occurred between 20 and 
94 months (mean 57.0 months) after the first visit, the annual malignant transformation 
rate being approximately 2.6%. A large size of the lesion (≥ 4 cm) showed to be the only 
statistically significant predictor of malignant transformation (p = 0.034).  
CONCLUSION: A size of ≥4 cm showed to be the only significant predicting factor of 
malignant transformation in oral leukoplakia. No other epidemiological, etiological,  
clinical or histopathological parameters were of statistical significance. 
Keywords: potentially malignant oral disorder; oral leukoplakia; malignant transformation; 
oral epithelial dysplasia; oral cancer
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Introduction 
 
Oral leukoplakia is a potentially malignant disorder which means that in this  
morphologically altered tissue, squamous cell carcinoma is more likely to occur than in its 
apparently normal counterpart1. The reported annual malignant transformation of oral  
leukoplakia into oral squamous cell carcinoma (OSCC) is approximately 1%- 2% 2.  
Several factors have been suggested to predict an increased risk of malignant  
transformation of oral leukoplakia, such as age, gender, tobacco habits, homogeneity and 
size of the lesion, oral subsite, degree of epithelial dysplasia, if present, loss of  
heterozygosity, surviving, matrix metalloproteinase 9, and DNA content2-9. The possible 
role of human papilloma virus infection with regard to malignant transformation of oral 
leukoplakia is at yet unclear10,11. Management of oral leukoplakia consists of surgical  
excision, laser surgery, CO
2
 laser vaporisation and observation12,13.  
          The aim of the present retrospective study was to identify the factors that possibly 
predict malignant transformation in a well defined cohort of patients with a long-term  
follow-up. All leukoplakias were staged according to a clinicopathological classification 
and staging system. Furthermore, a Certainty factor has been used with which the  
diagnosis has been established.  
Material and methods
Patients
For the purpose of this retrospective study, 144 consecutive patients were included who 
were referred to the Department of Oral and Maxillofacial Surgery and Oral Pathology 
at VU medical center/ ACTA, Amsterdam, The Netherlands, between 1997 and 2012 and 
in whom a definitive clinicopathological diagnosis of oral leukoplakia was established. 
In case of possible etiological factors, a period of maximum three months was allowed to 
evaluate the results of elimination of these factors. As a result, only patients with a  
diagnostic Certainty factor 3 and 4 have been included (Table 1) 14,15. The follow-up  
period lasted at least 12 months. Patients who developed a malignancy within a period of 
12 months after the biopsy (n = 2), have been excluded beforehand. In these two patients 
the initial biopsy may not have been representative.
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Table 1 Certainty (C)-factor of a diagnosis of oral leukoplakia14,15
C
1
 Evidence from a single visit, applying inspection and palpation as the only diagnosis 
means (Provisional clinical diagnosis), including a clinical picture of the lesion.
C
2
 Evidence obtained by a negative result of elimination of suspected etiologic factors, e.g. 
mechanical irritation, during a follow-up period of 6 weeks (Definitive clinical diagnosis)
C
3
 As C
2
, but complemented by pretreatment incisional biopsy in which, histopathologically, 
no definable lesion is observed (Histopathologically supported diagnosis) 
C
4
 Evidence following surgery and pathologically examination of the resected specimen
Table 2 Distribution of tobacco and alcohol habits among 144 patients with oral  
leukoplakia
Total Malignant transformation
n = 144 n = 16
Variable
Tobacco habits User 70 7
Non user 64 8
Unknown 10 1
Alcohol consumption User 68 8
Non user 26 3
Unknown 50 5
 The group of 144 patients consisted of 44 men and 100 women, with a mean age of 
58.7 years (SD= 14.11, range 26-98 years) (Figure 1). The use of tobacco and alcohol was 
registered in a simplified manner as being user, non user or unknown (Table 2).  
 In this study the definition of leukoplakia, as proposed by the WHO in 2005, has 
been used: “A predominantly white plaque of questionable risk having excluded (other) 
known diseases or disorders that carry no increased risk for cancer” 1. Clinically, a  
distinction was made between homogenous (flat, thin or wrinkled, uniform white in  
colour) and non-homogeneous (white or white-and-red, either speckled, nodular or  
verrucous) leukoplakia 1. There were 65 patients with a homogenous leukoplakia and 79 
with a non-homogeneous type. Although many patients had multiple or widespread  
leukoplakias, not a single one fully qualified to be characterized as proliferative verrucous 
leukoplakia as being described in the literature16,17.
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Figure 1 Distribution of gender and age in 144 patients with oral leukoplakia
          The location of leukoplakia was specified according to eight subsites: (i) tongue, (ii) 
floor of mouth (FOM), (iii) lower lip, (iv) hard palate, (v) buccal mucosa, (vi) upper  
alveolus and gingiva, (vii) lower alveolus and gingiva and (viii) multiple sites (Table 3). 
 
Table 3 Site distribution of 144 patients with oral leukoplakia
Total Malignant transformation
n = 144 n = 16
Oral subsite
Tongue (dorsal and lateral surfaces) 43 8
Floor of mouth 25 1
Lower lip 3 1
Hard palate 10 2
Cheek mucosa 9 2
Upper alveolus and gingiva 13
Lower alveolus and gingiva 18
Multiple sites 23 2
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In all patients clinical pictures of the oral leukoplakia were taken at the first visit and in 
most cases also during follow-up, particularly in case of recurrence or malignant  
transformation. The clinical picture taken at the first visit was used for this study. The size, 
presence and degree of epithelial dysplasia were incorporated in the OL-classification and 
staging system (Table 4) 2. There were 95 incisional and 49 excisional biopsies. In eleven 
patients there was an additional excision specimen available for histopathological grading. 
In five of the eleven patients the final histopathological examination resulted in a  
different P-classification; the highest pathological score was used in these cases. All  
histological sections were revised by the same pathologists (EB/IW); in a limited number 
of cases that were graded differently, a consensus was arrived (Table 5). In 53 patients 
PAS-D sections were available for assessment of the presence of Candida albicans. In 
14/53 (26%) sections, Candida albicans was present.
 Table 4 Classification and staging system for oral leukoplakias (OL-system) 
 L (size of the leukoplakia)
L
1 
Size of single or multiple leukoplakias together <2 cm
L
2 
Size of single or multiple leukoplakias together 2-4 cm
L
3 
Size of single or multiple leukoplakias together >4 cm
Lx Size not specified 
P (pathology)
P
0 
No epithelial dysplasia (includes “perhaps mild epithelial dysplasia”)
P
1 
Mild or moderate epithelial dysplasia
P
2 
Severe epithelial dysplasia (includes “perhaps carcinoma in situ”) 
Px Absence or presence of epithelial dysplasia not specified in the pathology   report
 OL-staging system
Stage 1 L
1
P
0
Stage 2 L
2
P
0
Stage 3 L
3
P
0
 or L
1
L
2
P
1
Stage 4 L
3
P
1
 or any L P2
General rules of the OL-staging system 
1. If there is doubt concerning the correct L category to which a particular case should be           
    allotted, than the lower (i.e. less advanced) category should be chosen. This will also be      
    reflected in the stage grouping. 
2. In case of multiple biopsies of single leukoplakia or biopsies taken from multiple  
    leukoplakias the highest pathological score of the various biopsies should be used. 
3. Distinct carcinoma in situ has been excluded from this classification. 
4. For reporting purposes the oral subsite according to the ICD-DA should be mentioned              
    (World Health Organisation, International Classification of Diseases. Tenth Revision.  
    Application to Dentistry and Stomatology, ICD-DA, Geneva, 1992).
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Table 5 Size, histopathology and stage in 144 patients with a definitive clinicopathological 
diagnosis of oral leukoplakia.
Total Malignant transformation
n  = 144 n =16 
Variable
Size L
1
67 4
L
2
42 4
L
3
35 8
Dysplasia P
0
88 8
P
1
40 6
P
2
16 2
OL-staging system Stage 1 39 1
Stage 2 29 3
Stage 3 51 7
Stage 4 25 5
 
Management and treatment
The initial treatment was performed within six months after the first visit to the clinic. In 
71/144 (49.3%), initial treatment consisted of surgical excision (n = 49) or CO
2
 laser  
vaporisation (n = 22). CO
2
 laser vaporisation was mainly used in non-dysplastic  
leukoplakias and leukoplakias at sites that were less amenable for surgical excision, such 
as floor of the mouth and mucobuccal folds. In most cases a margin of a few millimeters 
clinically normal looking mucosa was observed. In 73/144 (50.7%) of the patients, initial 
management consisted of observation. The treatment modalities during follow-up of these 
patients consisted of surgical excision (n = 11) and CO
2
 laser vaporisation (n = 13).  
Forty-nine patients never underwent any type of treatment. 
 The follow-up period ranged from 12 to 179 months with a mean of 51.2 months 
(SD= 39.33). Follow-up visits were scheduled at 3 or 6 months intervals. The follow-up 
period started at the first visit of the patient to the clinic. It ended in case of lost to  
follow-up, death, development of OSCC at the site of the leukoplakia or elsewhere in the 
oral cavity or the head and neck region. 
 The design of this study adheres to the code for proper secondary use of human  
tissue of the Dutch Federation of Biomedical Scientific Societies (http://www.federa.org)18.  
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Statistical analysis
Minimum, maximum, and mean values of continuous variables were calculated.  
Statistically significant relations were tested with the Chi-square test. The results were 
statistically significant if the p-value was less than 0.05. The limited number of patients 
did not allow to perform a multivariate analysis. For malignant transformation, a survival 
curve was plotted according to the Kaplan-Meier method. For all statistical analyses, SPSS 
17.0 for Windows (SPSS Inc, Chicago, IL, USA) was used. 
Results
Malignant transformation
In 16/144 (11%) patients, four men and twelve women, malignant transformation occurred 
during follow-up (Figure 2). There was no statistical significant relation between malignant 
transformation and gender (p = 0.609). The age of these sixteen patients ranged from 26-81 
years (SD= 14.11, mean 58.2-years). The age of the patients with malignant transformation 
was categorized into 60 years and older (n = 10) and less than 60 years (n = 6); age was not 
related to malignant transformation (p = 0.593). Five patients had tobacco habits and six  
patients regular used alcohol. Also tobacco habits and regular alcohol use were not  
associated with malignant transformation (p = 0.894 and p = 0.953, respectively).  
Malignant transformation occurred between 20 and 94 months (mean 57.0 months) after 
the first visit, the annual malignant transformation rate being approximately 2.6%.  
          Four oral leukoplakias were homogeneous and 12 non-homogeneous. No statistically 
significant relation was found between the clinical appearance and malignant  
transformation (p = 0.086). The oral leukoplakias were located at the tongue (n = 8), FOM 
(n = 1), lower lip (n = 1), hard palate (n = 2), buccal mucosa (n = 2) and multiple sites (n 
= 2). No statistically significant relation was found between the oral subsite and malignant 
transformation (p = 0.144), even when the subsites were subdivided into high-risk (floor of 
mouth and tongue) versus low-risk (remaining oral subsites) (p = 0.408). All carcinomas 
arose at the same subsite of the oral leukoplakia. Four oral leukoplakias were L
1
 in size, 
four were L
2
 and eight lesions were L
3
. A large size of the lesion (L
3
 ≥ 4 cm in largest  
diameter) showed to be a predictor for malignant transformation (p = 0.034).  
 The initial biopsy showed no dysplasia (P
0
) in 10 patients, while in two atients 
mild/moderate dysplasia (P
1
) and in two other cases severe epithelial dysplasia (P
2
) was 
observed. No statistically significant relation was found between the presence and 
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Figure 2 Kaplan-Meier analysis of malignant transformation in oral leukoplakia (n = 144)
 
degree of epithelial dysplasia and malignant transformation (p = 0.604); this was also true 
when using a binary system, i.e. no dysplasia (P
0
) and presence of dysplasia (P
1
 and P
2
)  
(p = 0.334). The patients were also staged according to the OL-classification and staging  
system: Stage 1 (n = 1), Stage 2 (n = 3), Stage 3 (n = 7) and Stage 4 (n = 5). Stage was not 
a statistically significant factor (p = 0.187). Of the 16 patients with a malignant  
transformation PAS-D sections were available in eight cases of which four were positive 
for Candida albicans (p = 0.101).  
Management and treatment
The initial treatment of the 16 patients with a malignant transformation, consisted of  
surgical excision (n = 3), CO
2
 laser vaporisation (n = 3) and observation (n = 10).  
Treatment during follow-up of the patients with initial observation consisted of surgical 
excision (n = 2) and CO
2
 laser vaporisation treatment (n = 2). Six patients (37.5%) never 
underwent any type of active treatment. 
 Of the 60 patients who underwent surgical excision as the initial treatment  
(n = 49) or during follow-up (n = 11), 25 (42%) patients had a recurrence in a mean  
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follow-up period of 48.8 months. There was no statistically significant relation between 
recurrence after surgical excision and malignant transformation (p = 0.134). Of the 35 
patients who underwent CO
2
 laser vaporisation as the initial treatment (n = 22) or during 
follow-up (n = 13), 14 (40%) patients had a recurrence in a mean follow-up period of 61.9 
months19. There was no statistically significant relation between recurrence after CO
2
 laser 
vaporisation and malignant transformation (p = 0.324) 19.  
 Patients who underwent active treatment (surgical excision or CO
2
 laser  
vaporisation) (n = 95) did not have a statistically significant lower risk for malignant  
transformation than patients managed by only observation (n = 49) (p = 0.756). 
Discussion
In the present study, 144 patients with a histopathological diagnosis of oral leukoplakia and 
a minimum follow-up of 12 months were included. Moreover, a classification and staging 
system has been used (Table 1 and 4) 2,14,15. There were 16/144 (11%) patients in whom a 
malignant transformation occurred during the follow-up, resulting in an annual malignant 
transformation rate of 2.6%. Ninety-five out of 144 (66%) patients underwent any type of 
treatment at the initial stage or during follow-up, while in a previous study from our  
institute only 87/166 (52%) underwent any type of active treatment4. In the latter study the 
annual malignant transformation rate amounted 2.9% 4. Apparently, active or passive  
management policy is not related to malignant transformation. This observation has also 
been made in various other studies4,20,21. It is actually unknown whether the width of the 
margin, either in surgical removal or CO
2  
laser vaporisation, would be of relevance in this 
respect. At present, no molecular are available to determine the optimal width of the  
margin. 
 The gender distribution of the entire patient group showed a female preponderance 
with a male : female ratio of approximately 1 : 2,3 (Figure 1). Of the patients with  
malignant transformation the male : female ratio is even 1 : 3,7. In most long-term  
follow-up studies of oral leukoplakia there is a preference for males in the entire patient 
group22-25. However, other studies have shown that female gender was a higher risk for  
malignant transformation4,26. Despite of the high female preponderance in the present 
study no statistically significant difference was found between gender and malignant  
transformation (p = 0.609).  
 A large size of the lesion (L
3
 ≥ 4 cm) showed to be the only significant predictor 
of malignant transformation (p = 0.034). This relationship has also been shown in another 
study 5. As mentioned by Saito et al.25, widespread multiple leukoplakias have a higher  
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potential for the development of cancer than the localized ones. These authors also  
mentioned that their multiple leukoplakias probably represented examples of  
proliferative verrucous leukoplakia. The latter term has been the subject of discussion  
related to its definition for several decades. Anyhow, every leukoplakia, how small and 
how benign histopathologically looking, may turn into malignancy and that widespread 
multiple leukoplakias carry a higher risk of malignant transformation than localized, small 
ones. 
 Of the patients with a malignant transformation, eight carcinomas arose at the 
tongue and not one at the upper or lower alveolus and gingiva (Table 3). There was no  
statistically significant relation found between the oral subsite and malignant  
transformation (p = 0.144) and also not when the subsites were subdivided into high-risk 
(floor of mouth and tongue) versus low-risk (remaining oral subsites) (p = 0.408). We also 
did not identify “alveolar ridge keratosis” as a separate entity and we did not exclude cases 
of “frictional keratosis of the attached gingiva” that did not disappear after changing the 
brushing habits27-29. 
 Other reported predicting factors of malignant transformation such as age, the  
absence of tobacco habits, heterogeneity of the lesion, presence of C. albicans and presence 
and degree of epithelial dysplasia were not found in the present study4,5,7,30-32.  
 In 11 patients, surgical excision was performed after an incisional biopsy. The  
advantage of additional surgical excision after an incisional biopsy is the availability of a 
surgical specimen for additional histopathological examination. It has been shown that the 
histopathological findings in an incisional biopsy from leukoplakia are not always  
representative of the entire lesion33,34.  
 No reliable comparison can be made in our study between the treatment results of 
CO
2
 laser vaporisation and cold knife surgery, because of different indications for both 
treatment modalities in the present study. In the literature, no randomized controlled trials 
are available to compare both treatment modalities with regard to the local recurrence rate 
and the risk of malignant transformation. For both treatment modalities, high recurrence 
rates have been reported in the literature19,34,35. The present study showed for both surgical 
excision and CO
2
 laser vaporisation treatment a recurrence rate of approximately 40%  
during a mean follow-up period of 48.8 and 61.9 months, respectively.  
 The annual malignant transformation rate (2.6%) in this study may be difficult to 
compare with that of other studies, due to possible differences in study populations,  
different tobacco and alcohol habits, different diagnostic criteria used for oral leukoplakia 
and allied white lesions, different treatment strategies and perhaps also different follow-up 
policies. A size of ≥4 cm showed to be the only significant predicting factor of malignant 
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transformation in oral leukoplakia. No other epidemiological, etiological, clinical or  
histopathological parameters were shown to be of statistical significance. Although the  
efficacy of removal of oral leukoplakia with regard to the risk of malignant transformation 
is uncertain, such removal should be considered in each patient with  such lesion,  
particularly also in the extensive ones.
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Abstract
The estimated prevalence of oral leukoplakia is worldwide approximately 2%, with an  
annual malignant transformation rate of approximately 1%. The aim of the present study 
was to evaluate the possible contribution of ploidy measurement to the prediction of the 
clinical course, in a well defined cohort of patients with oral leukoplakia. Ploidy was  
measured by both flow cytometry (FCM-DNA) and image cytometry (ICM-DNA) and we 
focussed on the comparison of the two different techniques to determine ploidy. A total 
of 41 patients have been included, with a mean age of 59 years (range 36-78 years). With 
FCM-DNA, three lesions were aneuploid, with ICM-DNA, 19 lesions were aneuploid. 
DNA ploidy was compared with clinicopathological and patients parameters. There were 
no statistically significant differences between DNA ploidy and any patient factor with 
both FCM-DNA and ICM-DNA. Using FCM-DNA, DNA aneuploid lesions showed  
statistically significant more dysplasia (p = 0.04) than diploid lesions. Furthermore, DNA 
aneuploid lesions were more frequently encountered at high-risk locations (p = 0.03) as 
being determined with FCM-DNA. These relations were not found when DNA ploidy was 
determined with ICM-DNA.
  
Keywords: DNA ploidy, flow cytometry, image cytometry, oral epithelial dysplasia, oral 
leukoplakia, oral squamous cell carcinoma, potentially malignant disorder
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Introduction
 
Leukoplakia is defined as “a white plaque of questionable risk having excluded (other) 
known diseases or disorders that carry no increased risk for cancer” 1. The estimated  
prevalence of oral leukoplakia worldwide is approximately 2% 2, with an annual malignant 
transformation rate into oral squamous cell carcinoma (OSCC) of approximately 1% 3. 
Several factors are known to be associated with an increased risk of malignant  
transformation of leukoplakia, e.g. homogeneity and size of the lesion3-5. At present, the 
best predictor is the presence of epithelial dysplasia. Nevertheless, some dysplastic lesions 
may remain unchanged or resolve over time6,7. A limitation of dysplasia grading is its  
relative subjective character, indicated by a high inter- and intra-examiner variability in the 
assessment of dysplasia8-11.  
Another suggested parameter of prognostic value could be DNA ploidy measurement12. 
DNA aneuploid lesions in Barrett’s esophagus have shown a higher risk of malignant  
transformation13 and DNA aneuploid gastric cancer has an unfavourable prognosis  
compared to DNA diploid cancer14. Recent DNA ploidy studies of dysplastic oral lesions 
have suggested that DNA aneuploid lesions carry a higher risk for OSCC progression15-18. 
The DNA ploidy status can be measured by either flow cytometry (FCM-DNA) or image 
cytometry (ICM-DNA). 
 The aim of the present study was to evaluate the possible difference between DNA 
ploidy measurement using either FCM-DNA or ICM-DNA, in a well defined cohort of 
patients with oral leukoplakia. This study is a continuation of the study of Bremmer et 
al.18. Relations between DNA ploidy and the histopathological grading and other clinical 
parameters, such as gender, smoking habit, alcohol consumption, homogeneity, size and 
location of the lesion were investigated. Moreover, all leukoplakias were classified by the 
OL-classification and staging system3. 
Material and methods
Patients
For the purpose of this retrospective study, 87 patients were selected on the basis of  
biopsied leukoplakias with sufficient material for histopathological grading as well for 
DNA ploidy measurement, and a minimum follow-up time of 12 months. All patients were 
referred to the Department of Oral and Maxillofacial Surgery at VUmc/ACTA, Amsterdam, 
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and the biopsies were taken between 2003-2010. Patients with an (previous or  
concomitant) OSCC were excluded (n = 8). Also, patients in whom DNA ploidy could not 
be determined were excluded (n = 38). A total of 41 out of 87 patients fulfilled all inclusion 
criteria: 20 men and 21 women, with a mean age of 59 years (range 36-78 years). Nine  
patients in this cohort overlapped between this study and the study by Bremmer18. The 
smoking habits and alcohol consumption of these patients are shown in Table 1.
Table 1 Distribution of tobacco and alcohol habits among 41 patients with oral leukoplakia
 
Gender Patients Tobacco Alcohol
Smoker Non smoker Unknown Use No use Unknown
Men 20 12 6 2 10 4 6
Women 21 14 5 2 6 4 11
Total 41 26 11 4 16 8 17
Clinically, a distinction was made between homogenous and non homogeneous  
leukoplakia. There were 28 patients with a homogeneous leukoplakia and 13 with the non 
homogeneous type. The location of leukoplakia was specified according to six subsites: 
tongue, floor of mouth (FOM), hard palate, buccal mucosa, upper and lower alveolus and 
gingiva, and multiple sites (Table 2). All this information was extracted from the patient 
files.
 
Table 2 Site distribution of 41 patients with leukoplakia 
Oral subsite Number of patients
Tongue (dorsal and lateral surfaces) 10
Floor of mouth 7
Hard palate 3
Cheek mucosa 5
Upper and lower alveolus and gingiva 4
Multiple site 12
Total 41
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The size, presence and grade of epithelial dysplasia were determined by means of the  
OL-classification and staging system (table 3) 3. Twenty-three leukoplakias were L
1
, 10 
cases were L
2
 and 7 were L
3
. Size could not be determined in one case. There were 23  
excisional and 18 incisional biopsies performed. All biopsies were revised on  
haematoxylin and eosin (H&E) stained sections by the same investigators (EREAB/EB), a 
joint consensus was made for the cases that were graded differently. Severe dysplasia (P
2
) 
was diagnosed in six biopsies, mild-moderate dysplasia (P
1
) in 14 biopsies, while dysplasia 
was absent (P
0
) in 21 biopsies. The biopsy on which the histological grading was done, was 
also used for DNA ploidy determination.
 Table 3 Classification and staging system for oral leukoplakias (OL-system) 
 
 L (size of the leukoplakia)
L
1 
Size of single or multiple leukoplakias together <2 cm
L
2 
Size of single or multiple leukoplakias together 2-4 cm
L
3 
Size of single or multiple leukoplakias together >4 cm
Lx Size not specified 
P (pathology)
P
0 
No epithelial dysplasia (includes “perhaps mild epithelial dysplasia”)
P
1 
Mild or moderate epithelial dysplasia
P
2 
Severe epithelial dysplasia (includes “perhaps carcinoma in situ”) 
Px Absence or presence of epithelial dysplasia not specified in the pathology   report
 OL-staging system
Stage 1 L
1
P
0
Stage 2 L
2
P
0
Stage 3 L
3
P
0
 or L
1
L
2
P
1
Stage 4 L
3
P
1
 or any L P2
General rules of the OL-staging system 
1. If there is doubt concerning the correct L category to which a particular case should be           
    allotted, than the lower (i.e. less advanced) category should be chosen. This will also be      
    reflected in the stage grouping. 
2. In case of multiple biopsies of single leukoplakia or biopsies taken from multiple  
    leukoplakias the highest pathological score of the various biopsies should be used. 
3. Distinct carcinoma in situ has been excluded from this classification. 
4. For reporting purposes the oral subsite according to the ICD-DA should be mentioned              
    (World Health Organisation, International Classification of Diseases. Tenth Revision.  
    Application to Dentistry and Stomatology, ICD-DA, Geneva, 1992).
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Initial and follow-up management included surgical excision, CO
2
-laser therapy or  
observation. All patients were advised to quit smoking19. The follow-up period ranged from 
12 to 87 months with a median of 20 months. The follow-up period started at the date the 
biopsy was taken. It ended in case of lost to follow-up, death, or development of OSCC at 
the site of oral leukoplakia or elsewhere in the oral cavity. 
 The design of this study adheres to the code for proper secondary use of human  
tissue of the Dutch Federation of Biomedical Scientific Societies (http://www.federa.org)20. 
 
Tissue processing for FCM-DNA and ICM-DNA
Formalin fixed paraffin-embedded tissue specimens, the same which were used for  
histopathological grading, were collected from the pathology archive. Two or three 50 µm 
sections were cut from the tissue specimens and nuclear cell suspensions were prepared 
according to the Hedley procedure21. For FCM-DNA, part of the nuclear suspension was 
stained with DAPI (4’,6-diamidino-2-phenylindol, Partec Instruments, Muenster,  
Germany). For ICM-DNA, cytospins were prepared from the other part by centrifugation 
of the specimen for 15 min at 3000 rpm. The cytospins for ICM-DNA were stained using 
the Feulgen method according to the consensus of the European Society for Analytical 
Cellular Pathology22, with minor modifications. Cytospin preparations were placed in 5 N 
HCL for 30 min at 27°C. Hereafter the cytospins were rinsed in distilled water for 5 min, 
stained with fresh Schiff’s reagent for 45 min, and then washed in running tap water for 15 
min. Last, the cytospin slides were dehydrated and cover slipped.  
Measurement of FCM-DNA
The FCM-DNA measurements were done within 3 h after DAPI staining. For the  
measurements a Partec Pas II mercury lamp-based flow cytometer (Partec Instruments) was 
used. Trout erythrocytes were used as external control cells. The procedure is described in 
detail elsewhere23.
 
Measurement of ICM-DNA
The DNA content of stained nuclei was measured and analysed by ICM-DNA according 
to a published protocol14,24. The guidelines of the consensus report of the European Society 
for Analytical Cellular Pathology were followed22. Köhler illumination was applied,  
before every ICM-DNA analysis. The camera was switched on at least 15 min before every 
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measurement to ensure standardised conditions. Images were linearly corrected for shading 
with two empty images, namely one illuminated and one dark-current image25. The  
resulting corrected grey values provided a measure for the local optical density.  
Segmentation was carried out in a fully automatic manner14,24. A filter was used during 
measurements to remove debris and aggregates. 
 Approximately, 1000 nuclei were measured in a fully automatic manner.  
Lymphocytes and fibroblasts were included as internal DNA diploid controls and were 
used to calibrate and scale the DNA histogram. Using classification algorithms, round dark 
condense objects resembling lymphocytes and ellipsoid objects resembling fibroblasts were 
automatically identified. The majority of remaining debris and aggregates were  
automatically removed with another set of classification algorithms from the data set. The 
resulting DNA histograms were visually inspected. Nuclei, which should have been  
removed on the basis of features such as shape and texture automatically, but were missed 
by the classification algorithms, were removed manually. 
 In DNA cytometry, nuclear DNA content is measured in relative units ‘c’, in which 
the DNA content of normal nuclei is set at 2c. In this study, the 2c reference value was  
determined by taking the mean DNA content measured for nuclei that were identified as 
lymphocytes and fibroblasts. After establishing the 2c reference value, the histogram was 
scaled up to 10c with a fixed number of 256 bins to obtain standardised histograms that 
cover a wide range of c values that potentially occur in populations of tumour nuclei14. 
Analysis of DNA histogram FCM-DNA and ICM-DNA
The DNA histograms were analysed using the MultiCycle AV computer programme  
(Phoenix Flow Systems, San Diego, CA, USA), according to a previously described  
protocol26. The DNA index was calculated by dividing the modal channel number of DNA 
aneuploid peaks by the corresponding number of the DNA diploid peak. In case of only 
one cell cycle, the DNA index was set at 1.00. All FCM-DNA and ICM-DNA cases were 
classified in two subclasses, based on previous published guidelines as follows22: DNA  
diploid (only one cell cycle present) and DNA aneuploid (DNA index ≥1.1).
 
Statistical analysis
Minimum, maximum, mean, and median values of continuous variables were calculated. 
Relevant data were cross-tabulated. Statistically significant relations were tested with the 
Chi-square test. The variables age, gender, smoking habit, alcohol consumption,  
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homogeneity, dysplasia, size of the lesion, location and DNA ploidy were used. The results 
were statistically significant if the P-value was less than 0.05. For all statistical analyses, 
SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA) was used. 
Results
Ploidy measurement by flow (FCM-DNA) and image cytometry (ICM-DNA) 
In this study, 38 leukoplakias were DNA diploid and three were DNA aneuploid using 
FCM-DNA. However, by ICM-DNA, 19 leukoplakias were found to be DNA aneuploid 
(n.s.) (Table 4). Concordance between FCM-DNA and ICM-DNA was present in two  
lesions which were DNA aneuploid with both methods. However, one lesion was DNA  
aneuploid using FCM-DNA, but DNA diploid with ICM-DNA. Seventeen lesions that 
were DNA diploid by FCM-DNA measurement were DNA aneuploid using ICM-DNA. 
 
 
Table 4 DNA ploidy in leukoplakia using 2 different methods
ICM-DNA
Aneuploid Diploid Total
FCM-DNA Aneuploid 2 1 3
Diploid 17 21 38
Total 19 22 41
Relation between clinicopathological parameters and ploidy measured by flow cytometry 
(FCM-DNA)
All DNA aneuploid lesions (n = 3) showed mild-moderate epithelial dysplasia (P
1
). In total, 
18% of the dysplastic leukoplakias and 7% of the whole patient group were DNA  
aneuploid using FCM-DNA. In contrast to DNA diploid lesions, DNA aneuploid lesions 
always showed dysplasia (p = 0.04) (Table 5). The DNA aneuploid leukoplakias were  
located at the FOM (n = 2) and lateral tongue (n = 1). When the location of the lesions was 
divided between high-risk (FOM and tongue) versus low-risk (remaining), DNA aneuploid 
lesions occurred  
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Table 5 Histopathological grading and DNA ploidy in 41 patients with oral leukoplakia
FCM-DNA ICM-DNA
Diploïd Aneuploïd Diploïd Aneuploïd
Dysplasia P
0
21 0 13 8
P
1
11 3 8 6
P
2
6 0 1 5
statistically significantly more often at the high-risk locations (p = 0.03). All DNA  
aneuploid lesions were homogeneous. Two patients with DNA aneuploid lesions were 
smoker, one was a non smoker. Two lesions were small (L
1
), while one lesion was L
2
. The 
DNA aneuploid leukoplakia in the non smoker was homogeneous, L
1
 and located at the 
lateral tongue. There were no statistically significant differences between DNA aneuploid 
and DNA diploid lesions with regard to gender (p = 0.52), smoking habit (p = 0.83) and 
alcohol consumption (p = 0.52), homogeneity (p = 0.22), size (p = 0.85) or type of biopsy 
(p = 0.70). 
 
Relation between clinicopathological parameters and ploidy measured by image cytometry 
(ICM-DNA)
Of the DNA aneuploid lesions as determined by ICM-DNA (n = 19) eight showed no  
dysplasia (P
0
), six were P
1
 and five were P
2
 (Table 5). In total, 55% of the dysplastic  
leukoplakias and 46% of the whole patient group were DNA aneuploid using ICM-DNA. 
Although there was no statistically significant difference in dysplasia between DNA  
diploid and DNA aneuploid lesions (p = 0.14), there was a trend of more severe dysplasia 
in DNA aneuploid lesions (Table 5). There were no statistically significant differences  
between DNA aneuploid and DNA diploid lesions with regard to gender (p = 0.68),  
smoking habit (p = 0.32) and alcohol consumption (p = 0.47), homogeneity (p = 0.49),  
location (p = 0.26), size (p = 0.57) or type of biopsy (p = 0.68). 
 
Relation between clinicopathological parameters and dysplasia
In this study, 20/41 (50%) leukoplakias showed epithelial dysplasia, of which six cases se-
vere dysplasia (P
2
) (Table 5). Dysplasia (both P
1
 and P
2
) in leukoplakia was more often ob-
Chapter 6
90
served at the high-risk sites (tongue and FOM) than in low-risk sites (p = 0.02). There was 
no relation between dysplasia and gender (p = 0.61), age (p = 0.75), smoking habit  
(p = 0.61), alcohol consumption (p = 0.44), homogeneity (p = 0.08), or size of the lesion  
(p = 0.75).
 
Malignant transformation
In two out of 41 patients, two males, an OSCC developed in the leukoplakia during  
follow-up. The age of the patients at the time of OSCC diagnosis was 59 and 67 years,  
respectively. Both were smokers and only one of them used regular alcohol. Malignant 
transformation occurred 9 and 77 months after the initial biopsy was taken. The annual  
malignant transformation rate in this study is 0.6%. Both patients had multiple sites of  
leukoplakia. Leukoplakia was small (L
1
) in one and large (L
3
) in the other. The small lesion 
was severely dysplastic (P
2
), while the large lesion was non dysplastic (P
0
). Both  
leukoplakias were DNA diploid in FCM-DNA, but DNA aneuploid using ICM-DNA 
(DNA-index 1,24 and 1,32). The number of patients with malignant transformation in this 
cohort is too small and the length of follow-up may have been too short to allow statistical 
analysis. 
Discussion and conclusions
In the present study, 41 patients with oral leukoplakia and ploidy determination were  
included in the period between 2003-2010. There have been much more patients with an 
oral leukoplakia observed in this period, but not always a biopsy was taken.  
 It is questionable whether the histopathological findings in an incisional biopsy 
from a leukoplakia are representative of the entire lesion27; possibly, this also applies for 
the DNA ploidy measurement. 
 There is a big difference in the number of DNA aneuploid lesions as being  
determined with different techniques, viz. FCM-DNA and ICM-DNA. This may be  
explained by the use of different preparation techniques14. Another explanation might be 
that DNA aneuploid peaks detected by ICM-DNA are not seen in FCM-DNA when the 
number of aneuploid epithelial cells is only small or when large numbers of stromal and 
inflammatory cells are present14. On the other hand, there was one case of DNA aneuploidy 
assessed with FCM-DNA, which was DNA diploid with ICM-DNA. Possibly, false  
positive aneuploid lesions detected by FCM-DNA may be the result of clustering nuclei, 
unlike ICM-DNA, in which technique this clustering is excluded during the visual  
inspection14. 
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 In the present study, statistically significant relations were found between DNA  
aneuploidy determined with FCM-DNA and dysplasia. DNA aneuploid lesions assessed 
with FCM-DNA, occurred statistically significantly more often at high-risk locations. The 
latter finding is in agreement with another recent study28. There were no statistically  
significant outcomes with DNA ploidy, determined with both FCM-DNA and ICM-DNA, 
and any patient factor. In contrast, another recent study observed that the mean percentage 
of DNA aneuploid nuclei was statistically significant higher in smoking than in  
non-smoking patients habits29. 
 In the literature, the prevalence of DNA aneuploidy in non dysplastic and dysplastic 
lesions varies16-18,30-32. This can be due to the use of different sources of material, e.g. fresh 
frozen versus paraffin embedded tissue, different methods to prepare cytospins and  
different ways to interpret the DNA histograms. Moreover, in some studies only dysplastic 
lesions have been examined. 
 It should be noted that in the present study, both leukoplakias that progressed to an 
OSCC were DNA diploid with FCM-DNA, but DNA aneuploid with ICM-DNA,  
suggesting that the use of image cytometry is a more sensitive and clinically relevant  
parameter than using flow cytometry. Unfortunately however, there were not enough  
patients with progression to cancer to determine the possible relation between DNA ploidy 
(FCM-DNA and ICM-DNA) and malignant transformation. Although the exact role of 
DNA aneuploidy with regard to malignant transformation is still unknown, DNA  
aneuploidy should still be considered as a marker for malignancy12-17. 
Chapter 6
92
Reference list
 (1)  Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and  
  classification of potentially malignant disorders of the oral mucosa.  
  J Oral Pathol Med 2007;36(10):575-80.
 (2) Petti S. Pooled estimate of world leukoplakia prevalence: a systematic   
  review. Oral Oncol 2003;39(8):770-80.
 (3) van der Waal I. Potentially malignant disorders of the oral and    
  oropharyngeal mucosa; terminology, classification and present concepts of  
  management. Oral Oncol 2009;45(4-5):317-23.
 (4) Dietrich T, Reichart PA, Scheifele C. Clinical risk factors of oral    
  leukoplakia in a representative sample of the US population.    
  Oral Oncol 2004;40(2):158-63.
 (5) Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome  
  of oral premalignant lesions. Oral Oncol 2006;42(5):461-74.
 (6) Napier SS, Speight PM. Natural history of potentially malignant oral lesions  
  and conditions: an overview of the literature.      
  J Oral Pathol Med 2008;37(1):1-10.
 (7) Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical,  
  histopathological, and molecular biological characteristics.     
  Crit Rev Oral Biol Med 2003;14(1):47-62.
 (8)  Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial   
  dysplasia classification systems: predictive value, utility, weaknesses   
  and scope for improvement. J Oral Pathol Med 2008;37(3):127-33.
 (9)  Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, et  
  al. Intraexaminer and interexaminer reliability in the diagnosis of oral   
  epithelial dysplasia.          
  Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80(2):188-91.
 (10) Brennan M, Migliorati CA, Lockhart PB, Wray D, Al-Hashimi I, Axell T,   
  et al. Management of oral epithelial dysplasia: a review.    
  Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103Suppl:S19-2.
 CHAPTER
         6
DNA ploidy measurement in oral leukoplakia: 
different results between flow and image cytometry
93
 (11) Fleskens SAJH, Bergshoeff VE, Voogd AC, van Velthuysen ML, Bot FJ,   
  Speel EJ, et al. Interobserver variability of laryngeal mucosal premalignant  
  lesions: a histopathological evaluation. Mod Pathol 2011;24(7):892-8.
 (12) Sen S. Aneuploidy and cancer. Curr Opin Oncol 2000;12(1):82-8.
 (13) Fang M, Lew E, Klein M, Sebo T, Su Y, Goyal R. DNA abnormalities as   
  marker of risk for progression of Barrett’s esophagus to adenocarcinoma:   
  image cytometric DNA analysis in formalin-fixed tissues.     
  Am J Gastroenterol 2004;99(10):1887-94.
 (14) Belien JAM, Buffart TE, Gill AJ, Broeckaert MAM, Quirke P, Meijer GA,  
  et al. Gross genomic damage measured by DNA image cytometry  
  independently predicts gastric cancer patient survival.  
  Br J Cancer 2009;101(6):1011-8.
 (15) Bradley G, Odell EW, Raphael S, Ho J, Le LW, Benchimol S, et al.  
  Abnormal DNA content in oral epithelial dysplasia is associated with i 
  ncreased risk of progression to carcinoma.  
  Br J Cancer 2010;103(9):1432-42.
 (16) Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM. DNA ploidy  
  analysis by image cytometry helps to identify oral epithelial dysplasias with  
  a high risk of malignant progression. Oral Oncol 2009;45(6):468-73.
 (17) Pentenero M, Giaretti W, Navone R, Demurtas A, Rostan I, Bertolusso G, et  
  al. DNA aneuploidy and dysplasia in oral potentially malignant disorders:   
  association with cigarette smoking and site.       
  Oral Oncol 2009;45(10):887-90.
 (18) Bremmer JF, Brakenhoff RH, Broeckaert MAM, Belien JAM, Leemans CR,  
  Bloemena E, et al. Prognostic value of DNA ploidy status in patients with   
  oral leukoplakia. Oral Oncol 2011;47(10):956-60
 (19) Allard RHB. (The practice guideline ‘Treatment of tobacco addiction’).   
  Ned Tijdschr Tandheelkd 2005;112(6):216-24.
 (20) Oosterhuis JW, Coebergh JW, van Veen EB. Tumour banks: well-guarded   
  treasures in the interest of patients. Nat Rev Cancer 2003;3(1):73-7.
 
Chapter 6
94
 (21) Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method  
  for analysis of cellular DNA content of paraffin-embedded pathological ma 
  terial using flow cytometry. J Histochem Cytochem 1983;31(11):1333-5.
 (22) Haroske G, Baak JP, Danielsen H, Giroud F, Gschwendtner A, Oberholzer   
  M, et al. Fourth updated ESACP consensus report on diagnostic DNA image  
  cytometry. Anal Cell Pathol 2001;23(2):89-95.
 (23) Bergers E, van Diest PJ, Baak JP. Tumour heterogeneity of DNA cell cycle  
  variables in breast cancer measured by flow cytometry.     
  J Clin Pathol 1996;49(11):931-7.
 (24) Rijken AM, Belien JA, van Gulik TM, Polak MM, Offerhaus GJ,  
  Gouma DJ, et al. DNA quantitation of distal bile duct carcinoma measured  
  by image and flow cytometry. Anal Quant Cytol Histol 1999;21(4):303-10.
 (25) ten Kate TK, Belien JA, Smeulders AW, Baak JP. Method for counting   
  mitoses by image processing in Feulgen stained breast cancer sections.  
  Cytometry 1993;14(3):241-50.
 (26) Bergers E, van Diest PJ, Baak JP. Reproducibility of semi-automated cell   
  cycle analysis of flow cytometric DNA-histograms of fresh breast    
  cancer material. Anal Cell Pathol 1995;8(1):1-13.
 (27) Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Oral premalignant lesions: is a  
  biopsy reliable? J Oral Pathol Med 2007;36(5):262-6.
 (28) Islam MN, Kornberg L, Veenker E, Cohen DM, Bhattacharyya I. Anatomic  
  site based ploidy analysis of oral premalignant lesions.     
  Head Neck Pathol 2010;4(1):10-4.
 (29) Souto GR, Caliari MV, Lins CEC, de Aguiar MCF, de Abreu MHNG,   
  Mesquita RA. Tobacco use increase the number of aneuploid nuclei   
  in the clinically healthy oral epithelium.  
  J Oral Pathol Med 2010;39(8):605-10.
 (30)  Seoane J, Bascones A, Asenjo JA, Garcia-Pola M, Varela-Centelles PI. Flow 
  cytometric analysis of nuclear DNA content in oral leukoplakia.  
  Clin Otolaryngol Allied Sci 1998;23(2):136-40.
 CHAPTER
         6
DNA ploidy measurement in oral leukoplakia: 
different results between flow and image cytometry
95
 (31) Donadini A, Maffei M, Cavallero A, Pentenero M, Malacarne D, Di Nallo   
  E, et al. Oral cancer genesis and progression: DNA near-diploid  
  aneuploidization and endoreduplication by high resolution flow cytometry.  
  Cell Oncol 2010;32(5-6):373-83.
 (32) Saito T, Notani K, Miura H, Fukuda H, Mizuno S, Shindoh M, et al. DNA   
  analysis of oral leukoplakia by flow cytometry.  
  Int J Oral Maxillofac Surg 199;20(5):259-63.

 
 
 
Chapter 7
 
Summary, conclusions and recommendations

 CHAPTER
         7
Summary, conclusions and recommendations
99
Summary, conclusions and recommendations
In chapter 1, a general introduction is given about oral squamous cell carcinoma (OSCC) 
and oral premalignant disorders with emphasis on oral leukoplakia. Also, a list of  
definable white diseases and disorders, that may occur in the mouth and that do not carry 
an increased risk for the development of cancer is shown1. 
 In this thesis, an evaluation was made of the definition of oral leukoplakia, as being 
proposed by the WHO in 2005. Also the present molecular, clinical and histopathological 
factors of oral leukoplakia were evaluated, including the follow-up of a cohort of patients 
after treatment or observation only.
In chapter 2 an evaluation was presented of the definition of oral leukoplakia, proposed by 
the WHO in 2005, taking into account a previously reported classification and staging  
system2, including the use of a diagnostic Certainty factor of four levels with which the 
diagnosis of leukoplakia can be established2,3. 
 In the period 1997-2012 a hospital-based population of 275 consecutive patients 
with a provisional diagnosis of oral leukoplakia has been examined, 112 men and 163 
women, with a mean age of 57 years (range 17-98 years). In only 176 patients of these 275 
patients a firm diagnosis of leukoplakia has been established based on strict  
clinicopathological criteria. A flowchart is presented for the diagnosis of oral leukoplakia. 
The 176 patients have subsequently been staged using a classification and staging system 
based on size and histopathological features2,3.  
 For use in epidemiological studies it seems acceptable to accept a diagnosis of  
leukoplakia based on a single oral examination (Certainty level 1). For studies on  
management and malignant transformation rate the recommendation is made to include the 
requirement of histopathological examination of an incisional or excisional biopsy,  
representing Certainty level 3 and 4, respectively2,3. The recommendation is made to  
modify the present WHO definition of oral leukoplakia by adding the requirement of  
histopathological examination in order to obtain a definitive clinicopathological diagnosis. 
This recommendation results in the following definition of oral leukoplakia: “A  
predominantly white lesion or plaque of questionable behaviour having excluded, clinically 
and histopathologically, any other definable white disease or disorder”. Furthermore, we  
recommend the use of strict diagnostic criteria for predominantly white lesions for which a 
causative factor has been identified, e.g. smokers’ lesion, frictional lesion and dental  
restoration associated lesion. 
In chapter 3 an evaluation was made of the definition based on its use in the literature 
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of proliferative verrucous leukoplakia (PVL). PVL was first described by Hansen et al.4. 
Cerero Lapiedra et al (2010) proposed diagnostic criteria of PVL using a set of major and 
minor criteria5. Some of these criteria are well accepted, but others seem to be somewhat 
debatable. Therefore, a modified set of criteria has been proposed.
In chapter 4, the treatment results of CO
2
-laser vaporisation in a well defined cohort of  
patients with oral leukoplakia were presented. 
 The group of 35 patients consisted of 10 men and 25 women, with a mean age of 
55.5 years (range 26-87 years). Before treatment, a clinical photograph and an incisional 
biopsy were performed in all cases. Also the posttreatment results were documented with 
clinical photographs. The assessment of the treatment results was performed by an  
independent clinician who had not performed the treatment. The mean follow-up period 
was 61.9 months (range 12 to 179 months).  
 In 14/35 patients, there was a recurrence between 1 and 43 months (mean 18.7 
months), the annual recurrence rate being approximately 8%. In 3 of these patients,  
malignant transformation occurred at a later stage. In two other patients a malignancy  
occurred without a prior recurrence. In altogether 5/35 patients malignant transformation 
occurred in a mean period of 54 months, the annual malignant transformation rate being 
approximately 3%. 
 With regard to recurrences, the results in the present study are worse than those  
reported in the literature, perhaps due to a different use of diagnostic criteria for oral  
leukoplakia and allied white lesions and perhaps also due to a different way of assessing 
recurrence. The malignant transformation rate in the present study is more or less  
comparable with that of other studies. 
In chapter 5, the factors that possibly predict malignant transformation in a well defined 
cohort of patients with a long-term follow-up were reported.  All leukoplakias were staged 
according to a clinicopathological classification and staging system. Furthermore, a  
diagnostic Certainty factor has been used with which the diagnosis has been established. 
 The group consisted of 144 patients, 44 men and 100 women with a mean age of 
58.7 years (SD= 14.11, range 26-98 years). The size, presence and degree of epithelial  
dysplasia were incorporated in a clinicopathological classification and staging system.  
Initial management consisted of surgical excision, CO
2 
laser vaporisation or observation 
only. The mean follow-up period was 51.2 months (SD= 39.33, range 12-179 months). 
 In 16/144 patients (11%) malignant transformation occurred between 20 and 94 
months (mean 57.0 months) after the first visit, the annual malignant transformation rate 
being approximately 2.6%. A large size of the lesion (≥ 4 cm) showed to be the only  
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statistically significant predictor of malignant transformation (p = 0.034).  
 A size of ≥4 cm showed to be the only significant predicting factor of malignant 
transformation in oral leukoplakia. No other epidemiological, etiological, clinical or  
histopathological parameters were of statistical significance.
In chapter 6, the possible difference between DNA ploidy measurement using either flow 
cytometry (FCM-DNA) or image cytometry (ICM-DNA) in a well defined cohort of  
patients with oral leukoplakia has been described. This study is a continuation of the study 
of Bremmer et al.6. Relations between DNA ploidy and the histopathological grading and 
other clinical parameters, such as gender, smoking habit, alcohol consumption,  
homogeneity, size and location of the lesion have been  investigated. 
 A total of 41 patients have been included, 20 men and 21 women with a mean age 
of 59 years (range 36–78 years). Nine patients in this cohort overlapped between this study 
and the study by Bremmer et al.6. With FCM-DNA, three lesions were aneuploid and with 
ICM-DNA, 19 lesions were aneuploid. DNA ploidy was compared with  
clinicopathological and patient parameters. There were no statistically significant  
differences between DNA ploidy and any patient factor with both FCM-DNA and  
ICM-DNA. Using FCM-DNA, DNA aneuploid lesions showed statistically significant 
more dysplasia (p = 0.04) than diploid lesions. Furthermore, DNA aneuploid lesions were 
more frequently encountered at high-risk locations (p = 0.03) as being determined with 
FCM-DNA. These relations were not found when DNA ploidy was determined with  
ICM-DNA.
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Main conclusions and recommendations of this thesis
1. The use of strict diagnostic criteria is recommended for oral leukoplakia and  
predominantly white lesions for which a causative factor has been identified, e.g. 
smokers’ lesion, frictional lesion and dental restoration associated lesion.
2. A flowchart (Figure 1) for the diagnosis of oral leukoplakia is presented.
3. For use in studies on treatment results and malignant transformation, the  
recommendation is made to modify the present WHO 2005 definition of oral  
leukoplakia by adding the requirement of histopathological examination. As a  
result, we suggest: “A predominantly white lesion or plaque of questionable risk 
having excluded, clinically and histopathologically, (other) known diseases or  
disorders that carry no increased risk for the development of cancer”.
4. For use in epidemiological studies the requirement for histopathological  
examination to arrive at a diagnosis of leukoplakia may be dropped. As a result, 
we suggest: “A predominantly white lesion or plaque of questionable risk having 
excluded, clinically, (other) known diseases or disorders that carry no increased risk 
for the development of cancer”.
5. The choice of treatment of oral leukoplakia depends of the extent of the lesion, the 
oral subsite (e.g. floor of mouth) and the presence of dysplasia. In case of dysplasia, 
active treatment is recommended.  
6. CO2 laser vaporisation may be considered in case of location in the floor of the 
mouth, in  lesions larger than 2-3 cm, particularly if not well-circumscribed, and in 
the absence of moderate or severe dysplasia. It should be remembered that surgical 
excision has the advantage of enabling histopathologic examination of the entire 
lesion instead of just an incisional biopsy of part of the lesion.
7. Before CO2 laser vaporisation, an incisional biopsy is required in order to  
determine the presence and degree of dysplasia. 
8. No reliable comparisons can be made between the treatment results of CO2 laser 
vaporisation and cold knife surgical excision, because of different indications for 
both treatment modalities guided by oral subsite (e.g. floor of mouth), size of the 
leukoplakia and histopathological parameters, in particular the presence and degree 
of epithelial dysplasia.
9. The risk of malignant transformation of oral leukoplakia seems particularly  
increased in a large size of the lesion (≥ 4 cm).
 CHAPTER
         7
Summary, conclusions and recommendations
103
PTER
10. The exact role of DNA aneuploidy with regard to malignant transformation is still 
unknown. There is need for a single molecular marker or a set of markers in oral 
leukoplakia that predicts malignant transformation.
11. As mentioned by Einhorn and Wersäll already in 1967 there is no evidence that the 
incidence of oral carcinoma can be diminished by surgical removal of the  
leukoplakia but this does not mean that the operation should be abandoned, mainly 
for a histological diagnosis7.
12. There are no strict guidelines available for the duration and frequency of follow-up 
examinations. In general, lifelong follow-up examination is advised at 3-6 months 
intervals both in patients who have been treated for their leukoplakia as in those 
who have not. However, the efficacy of follow-up programs in oral leukoplakia has 
never been proven.
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In hoofdstuk 1, wordt een algemene introductie gegeven over mondkanker, orale  
premaligne afwijkingen en leukoplakie. Ook wordt er een overzicht gegeven van  
gedefinieerde witte ziekten en afwijkingen, die mogelijk kunnen voorkomen in de  
mondholte en die geen verhoogd risico hebben op het ontwikkelen van mondkanker1. 
 In dit proefschrift wordt er een evaluatie gemaakt van de definitie van leukoplakie, 
voorgesteld door de WHO in 2005. Ook moleculaire markers, klinische en  
histopathologische factoren van leukoplakie zijn onderzocht en er is een follow-up studie 
verricht van een cohort patiënten.
In hoofdstuk 2 wordt er een evaluatie gemaakt over de huidige definitie van leukoplakie, 
voorgesteld door de WHO in 2005. Tevens werd er een recent gepubliceerd classificatie- en 
stageringssysteem onderzocht2, als ook het gebruik van een Certainty factor van 4 niveaus 
waarmee de diagnostiek van leukoplakie kan worden gedaan 2,3.  
 In de periode 1997-2012, is een populatie van 275 opeenvolgende patiënten met 
een voorlopige diagnose van leukoplakie geïncludeerd; 112 mannen en 163 vrouwen, met 
een gemiddelde leeftijd van 57 jaar (range 17-98 jaar). Slechts 176/275 patiënten kregen 
een definitieve diagnose van leukoplakie, gebaseerd op strenge klinisch- pathologische  
criteria. Er  wordt een stroomdiagram gepresenteerd om tot de definitieve diagnose  
leukoplakie te komen. Deze 176 patiënten zijn gestageerd met behulp van een  
classificatie- en stageringssysteem. Dit systeem is gebaseerd op de grootte van de laesie en 
de histopathologische kenmerken2,3. 
 Voor epidemiologische studies, is het voldoende om de diagnose leukoplakie te 
baseren op enkel klinisch onderzoek (Certainty level 1). Voor studies over management 
en maligne ontaarding, is er de aanbeveling om altijd een histopathologisch onderzoek te 
verrichten door middel van een incisie of een excisie biopt, Certainty level 3 en 42,3. Er 
wordt een aanbeveling gedaan om de huidige WHO definitie te veranderen door er aan toe 
te voegen dat het noodzakelijk is om histopathologisch onderzoek te verrichten voor er een 
definitieve klinisch- pathologische diagnose van leukoplakie gemaakt kan worden. Deze 
aanbeveling heeft het volgende resultaat: “Een overwegend, witte slijmvliesverandering, 
die klinisch en histopathologisch niet als een andere witte afwijking kan worden  
gediagnosticeerd”. Bovendien wordt er aanbevolen om strikte criteria op te stellen voor  
overwegend, witte slijmvliesveranderingen waarin een oorzaak kan worden aangewezen, 
zoals rokerslaesies, wrijvingslaesies, en restauratie- geassocieerde laesies. 
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In hoofdstuk 3 wordt er een evaluatie gemaakt over de definitie van proliferatieve  
verruceuze leukoplakie (PVL) die bekend is in de literatuur. PVL is voor het eerst  
beschreven door Hansen et al.4. Cerero Lapiedra et al (2010) heeft een aantal criteria 
voorgesteld om tot de diagnose van PVL te komen, gebruikmakend van major en minor 
criteria5. Sommige van deze criteria zijn goed bruikbaar, over andere criteria kan  
gediscussieerd worden. In dit hoofdstuk worden daarom een aantal nieuwe criteria  
voorgesteld. 
In hoofdstuk 4 worden de behandelresultaten beschreven van een cohort patiënten met  
leukoplakie die behandeld zijn met CO
2
 laser verdamping.  
 De groep van 35 patiënten bestond uit 10 mannen en 25 vrouwen, met een  
gemiddelde leeftijd van 55.5 jaar (range 26-87 jaar). Voor behandeling, werd er in alle 
gevallen een klinische foto gemaakt en een incisie biopt verricht. Ook de postoperatieve 
behandelresultaten werden vastgelegd met een klinische foto. Het bekijken van de  
behandelresultaten werd uitgevoerd door een andere specialist dan door wie de  
behandeling was uitgevoerd. De gemiddelde follow-up tijd was 61.9 maanden (range  
12-179 maanden). 
 In 14/35 patiënten, trad er een recidief op tussen 1 en 43 maanden (gemiddelde 18.7 
maanden). Het jaarlijks recidiefpercentage is ongeveer 8%. In 3 van deze patiënten, trad er 
op een later moment een maligne ontaarding op. In 2 patiënten trad er een maligne  
ontaarding op, zonder vooraf gegaan door een recidief. In totaal trad er bij 5/35 patiënten 
een maligne ontaarding op na een gemiddelde periode van 54 maanden. Het jaarlijks  
maligne-ontaardingspercentage is ongeveer 3%.  
 In relatie tot de patiënten met een recidief na CO
2
 laser verdamping, zijn de  
resultaten in deze studie slechter dan gerapporteerd in de literatuur. Dit komt  
waarschijnlijk mede door verschillende criteria voor de diagnose van leukoplakie en andere 
witte slijmvliesafwijkingen, en ook door een andere beoordeling van de recidieven. Het 
maligne-ontaardingspercentage in deze studie is wel vergelijkbaar met andere studies.           
In hoofdstuk 5 zijn de factoren, die mogelijk een voorspellende waarde hebben voor een 
maligne ontaarding, onderzocht in een cohort van patiënten met een lange follow-up. Alle 
laesies zijn gestageerd met behulp van een klinisch- pathologisch stagerings- en  
classificatiesysteem. Bovendien is er ook een Certainty factor systeem gebruikt om tot de 
diagnose te komen. 
 De groep bestond uit 144 patiënten, 44 mannen en 100 vrouwen, met een  
gemiddelde leeftijd van 58.7 jaar (SD= 14.11, range 26-98 jaar). De grootte, aanwezigheid 
en graad van dysplasie is geïncorporeerd in een klinisch- pathologisch stagerings- en  
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classificatiesysteem. Initiële behandeling bestond uit chirurgische excisie, CO
2
 laser  
verdamping of alleen observatie. De gemiddelde follow-up periode was 51.2 maanden 
(SD= 39.33, range 12-179 maanden).  
 In 16/144 patiënten (11%), trad er een maligne ontaarding op tussen de 20 en 94 
maanden na het eerste bezoek van de patiënt. Het jaarlijks maligne-ontaardingspercentage 
is ongeveer 2.6%. Een grote laesie (≥ 4 cm) bleek de enige statistisch significante  
voorspeller voor maligne ontaarding (p = 0.034).  
 Een grootte van ≥ 4 cm bleek de enige statistisch significante voorspeller te zijn 
voor maligne ontaarding van leukoplakie. Geen andere epidemiologische, etiologische,  
klinische of histopathologische factoren waren statistisch significant. 
In hoofdstuk 6 wordt er gekeken naar het mogelijk verschil tussen DNA ploidy metingen 
gemeten met flow cytometrie (FCM-DNA) en image cytometrie (ICM-DNA) in een cohort 
van patiënten met leukoplakie. Deze studie is het vervolg op de studie van Bremmer et al6. 
De relaties tussen DNA ploidy en histopathologie en andere klinische parameters, zoals 
geslacht, leeftijd, roken, alcohol consumptie, homogeniteit, grootte en locatie van de laesie 
zijn onderzocht. 
 Een totaal van 41 patiënten is geïncludeerd; 20 mannen en 21 vrouwen met een 
gemiddelde leeftijd van 59 jaar (range 36-78 jaar). Negen patiënten in dit cohort  
overlappen met de studie van Bremmer et al.6. Met FCM-DNA, waren 3 laesies aneuploid 
en met ICM-DNA waren 19 laesies aneuploid. DNA ploidy werd vergeleken met  
klinisch- pathologische en patiëntgebonden factoren. Er waren geen statistisch significante 
relaties tussen DNA ploidy en een patiëntgebonden factor, zowel met FCM-DNA als met 
ICM-DNA. Met FCM-DNA, DNA aneuploïde laesies vertoonden statistisch significant 
meer dysplasie dan met ICM-DNA (p = 0.04). Ook waren DNA aneuploïde leasies,  
gemeten met FCM-DNA, frequenter aanwezig op predilictieplaatsen, zoals de tongrand 
en mondbodem (p = 0.03). Deze statistisch significante relaties konden niet aangetoond 
worden met ICM-DNA.
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Conclusies en aanbevelingen van dit proefschrift 
1. Het gebruik van strikte criteria wordt aanbevolen voor de diagnose van leukoplakie  
 en andere witte slijmvliesafwijkingen waarin een oorzaak aangewezen kan worden,  
 zoals rokerslaesies, wrijvingslaesies, en restauratie- geassocieerde leasies.  
2. Een stroomdiagram om tot een definitieve diagnose van leukoplakie te komen.
3. Voor studies over management en maligne ontaarding, wordt er aanbevolen om de  
 huidige WHO definitie te veranderen met de toevoeging dat het noodzakelijk is om  
 histopathologisch onderzoek te verrichten voor er een definitieve     
 klinisch-pathologische diagnose van leukoplakia gemaakt kan worden. Deze   
 aanbeveling heeft het volgende resultaat: “Een overwegend, witte     
 slijmvliesverandering, die klinisch en histopathologisch niet als een andere   
 witte afwijking kan worden gediagnosticeerd”.
4. Voor het gebruik in epidemiologische studies, is het voldoende om de diagnose   
 leukoplakie te baseren op enkel klinisch onderzoek. De definitie van leukoplakie is  
 dan “Een overwegend, witte slijmvliesverandering, die niet als een andere    
 witte afwijking kan worden gediagnosticeerd” 
5. Het type behandeling van leukoplakie hangt af van de grootte van de laesie, de  
 locatie in de mondholte (bijvoorbeeld de mondholte) en de aanwezigheid van  
 dysplasie. In het geval van dysplasie, wordt er een actieve vorm van behandeling   
 aanbevolen.
6. De behandeling CO2 laser verdamping wordt aanbevolen in het geval van locatie   
 op bijvoorbeeld de mondbodem, laesies die groter zijn dan 2-3 cm, niet duidelijk   
 begrensde laesies en in de afwezigheid van matig of ernstige dysplasie in het biopt.  
 Chirurgische excisie heeft de voorkeur boven CO2 laser verdamping, omdat er dan  
 histopathologisch onderzoek kan plaatsvinden op de gehele laesie in plaats van   
 slechts een klein gedeelte.
7. Voor CO2 laser verdamping moet er altijd een incisie biopt gedaan worden om de  
 aanwezigheid en graad van dysplasie te bepalen.  
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8. Er kunnen geen vergelijkingen gemaakt worden tussen de behandelresultaten van   
 CO2 laser verdamping en chirurgische excisie. Dit komt door de verschillende  
 indicaties voor deze behandelingen, zoals de locatie in de mondholte, de grootte   
 van de laesie en histopathologische factoren.
9. Het risico op maligne ontaarding is groter in laesies met een grootte van ≥ 4 cm. 
10. De exacte rol van DNA aneuploidy in relatie tot maligne ontaarding is nog steeds   
 onbekend. Er is noodzaak voor een enkele of een groep markers die maligne   
 ontaarding voorspellen.
11. Zoals al door Einhorn en Wersäll in 1967 omschreven, is er geen bewijs dat   
 maligne ontaarding kan worden voorkomen door chirurgische excisie van    
 leukoplakie. Dit betekent echter niet dat chirurgische excisie niet meer noodzakelijk  
 is.
12. Er zijn geen richtlijnen beschikbaar voor de duur en frequentie van de follow-up   
 onderzoeken. In het algemeen worden levenslang follow-up onderzoeken    
 aanbevolen, ongeveer elke 3-6 maanden. Zowel voor patiënten die een actieve   
 behandeling hebben ondergaan, als een passieve. Ondanks dat de efficiëntie van   
 follow-up onderzoeken nooit is bewezen.     
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